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Summary 
Acute myeloid leukemia (AML) is a hematopoietic cell disorder characterized by a 
block in differentiation and increased proliferation and survival of malignant blasts. 
Expansion of the malignant cell clone effects the normal production of blood cells and 
–  if left untreated  –  leads to death. Receptor tyrosine kinases (RTKs) play an 
important role in the pathogenesis of AML, as they are either often mutated or 
overexpressed. In normal hematopoiesis, RTK signal termination is tightly controlled, 
and involves ubiquitination, internalization, endocytosis and degradation. Cbl proteins 
are E3 ligases and have been shown to ubiquitinate several activated RTKs, 
including Flt3 and Kit, targeting them for degradation. Recently, several Cbl 
mutations have been identified: Cbl-R420Q was identified in an AML patient and Cbl-
70Z was identified in a mouse lymphoma model. In this thesis work, the role of these 
Cbl mutants in Kit signaling and in a mouse transplantation model was studied.  
Cbl mutants (Cbl-R420Q, Cbl-70Z) have the ability to transform the myeloid 32D cell 
line in cooperation with Kit WT. Cbl mutants along with Kit promoted interleukin-3 
(IL3)-independent proliferation and enhanced the cell survival of 32D cells. In 
contrast, expression of the Cbl mutants alone did not confer IL3-independent growth. 
Stem cell factor (SCF, the Kit ligand) dependent growth was enhanced in the 
presence of Cbl mutants and Cbl mutants promoted colonogenic growth in the 
presence of Kit. Furthermore, Cbl mutants inhibited the ubiquitination of the activated 
Kit receptor. In addition, Cbl mutants inhibited the endocytosis of the activated Kit 
receptor. Retroviral
 expression of Cbl mutants in transplanted bone marrow induced
 a 
generalized mastocytosis, a myeloproliferative disease and,
  in rare care  cases, 
myeloid leukemia. Splenomegaly was observed in the presence of Cbl mutants. 
Furthermore, mast cells with variable range of infiltration were noticed in all the vital 
organs (spleen, liver, bone marrow,
 lung, kidney, heart) of Cbl (mutant) transplanted 
mice. Almost all recipients of bone marrow cells transduced with Cbl mutants 
developed a lethal hematologic disorder with a mean latency of 341 days in the Cbl-
R420Q group and 395 days in the Cbl-70Z group. This is the first published report on 
a hematological disease with Cbl mutants in a mouse model. Co-immunoprecipitation 
studies indicated that Cbl-70Z binds to Kit, even in the absence of Kit ligand. Cbl-
R420Q also bound to Kit in the absence of SCF, albeit to a lesser extent. Association 
of Cbl mutants to Kit was enhanced in the presence of SCF. Summary 
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Signaling studies demonstrated the constitutive activation of Akt and Erk in the 
presence of Cbl mutants and Kit. In addition, Cbl mutants enhanced the SCF-
dependent Kit, Akt and Erk activation. Cbl-70Z, in association with kinase-dead Kit 
(Kit-KD) or kinase-dead Flt3 (Flt3-KD), conferred IL3-independent growth and 
survival to the myeloid 32D cell line. Cbl-R420Q provided only a slight growth 
advantage in the presence of Kit-KD. As demonstrated by pharmacological inhibition 
studies, Akt activation was necessary for the transformation mediated by Cbl-70Z 
and Kit-KD / Flt3-KD.  
Cbl mutants enhanced the Src family kinases (SFKs) activity. The pharmacological 
inhibition of SFK activity inhibited the proliferation and colonogenic growth. 
Interaction was found between Cbl-70Z, SFKs and Kit-KD. The SFK member Fyn 
was identified to bind to Cbl. In addition, kinase activity of SFKs was necessary for 
binding to Cbl, since SFKs inhibition by PP-2 abolished the binding between the 
complex-binding partners. Dasatinib and PP-2, both SFK inhibitors, inhibited the Cbl 
and Akt phosphorylation indicating that Fyn acts upstream of Akt. 
Inhibition of Kit with imatinib reduced the proliferation of cells
 overexpressing Kit WT 
and Cbl-70Z much stronger compared with cells
 expressing Kit-KD and Cbl-70Z, but 
much less than
 the dual KIT/SFK inhibitor dasatinib. This indicated that
 Kit kinase 
activity was required but not essential. The data presented in this thesis work implies 
that both RTK and SFK inhibition may have to be targeted, in order to effectively 
prevent transformation. In summary, the present thesis work indicates an important 
role of Cbl, Kit and SFKs in myeloid transformation and deregulated signal 
transduction. 
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1  Introduction 
1.1  Hematopoiesis 
Hematopoiesis is the process of blood cell formation. All cellular components of blood 
are derived from hematopoietic stem cells (HSC). The adult hematopoietic system 
produces one trillion blood cells every day. Hematopoietic stem cells possess the 
unique capability of self-renewal (Figure 1). The self-renewal property allows HSC to 
divide into two identical daughter cells, which have the same capability to produce 
blood cells as their parent HSC. Self-renewal allows HSC to maintain their number 
throughout life time. HSC can also differentiate to committed progenitor cells, which 
finally differentiate into mature blood cells. The majority of HSC reside in the bone 
marrow  with a few cells circulating in the peripheral blood (Cantor and Orkin, 
2001;Orkin, 1995;Orkin, 1996;Orkin and Zon, 2002). During embryogenesis, 
hematopoiesis occurs in different waves.  Mammalian hematopoiesis starts in the 
yolk sac, continues in the fetal liver and finally occurs in the bone marrow (Orkin, 
1995). 
Mature blood cells have a limited life span and must continuously replaced by new 
cells. In the presence of cytokines  HSCs proliferate and differentiate to common 
myeloid and lymphoid progenitors. Under control of appropriate cytokines, common 
myeloid progenitor cells further differentiate to form erythrocytes, granulocytes, 
monocytes, dendritic cells and megakaryocytes (Figure 1). Lymphoid progenitors, on 
the other hand, differentiate into T and B lymphocytes and natural killer (NK) cells 
(Figure 1) (Cantor and Orkin, 2001;Orkin, 1995). 
 
1.2  Leukemia 
Leukemia is a cancer of the blood or bone marrow and characterised by abnormal 
proliferation of white blood cells (WBC). These abnormal WBCs overcrowd the bone 
marrow and blood stream and are functionally impaired in fighting infectious agents. 
As leukemia progresses, it affects the formation of normal hematopoiesis, leading to 
decreased number of red blood cells (called anemia) and platelets (called 
thrombocytopenia). 
 
  Introduction 
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Figure 1. Hematopoiesis. The maturation and differentiation of cells during normal hematopoiesis is 
shown. Colony-forming units for the erythroid (CFU-E), megakaryocytic (CFU-MK), granulocytic–
monocytic (CFU-GM), basophilic (CFU-B), granulocytic (CFU-G), monocytic (CFU-M), and dendritic 
(CFU-D) lineages are shown. NK cell, natural killer cell; RBC, red blood cell. Taken from (Stirewalt and 
Radich, 2003) 
 
1.2.1  Classification of leukemia 
Leukemias are classified based on two characteristics:  
1  Based on the rate of disease progression, leukemias are either acute (rapidly 
developing) or chronic (slowly developing). 
2 Based on the type of bone marrow cell involved, leukemias are either of lymphoid 
or myeloid origin. 
 
Therefore, leukemias are classified into 4 types based on the above factors. Introduction 
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•  Acute myeloid (or myelogenous) leukemia (AML) 
•  Chronic myeloid (or myelogenous) leukemia (CML) 
•  Acute lymphocytic (or lymphoblastic) leukemia (ALL) 
•  Chronic lymphocytic leukemia (CLL) 
This thesis work focuses on the pathogenesis of AML. 
 
1.2.2  Acute myeloid leukemia (AML) 
AML is characterized by a differentiation block and expansion of early myeloid 
progenitor cells. This results in the accumulation of functionally impaired myeloblasts 
(called leukemic blasts) in the bone marrow and blood. The incidence of AML 
increases with age and less common in children and young adults (Appelbaum et al, 
2001;Lowenberg et al, 1999). Numerous balanced translocations and mutations have 
been identified to date in AML (Brandts et al, 2007a). Genetic alterations found in 
AML have been divided into two classes of mutations (Kelly and Gilliland, 2002a). 
The first class of mutations, also termed class I mutations, confer a proliferative 
and/or survival advantage to the hematopoietic cells. Examples include  activating 
mutations in the receptor tyrosine kinases Flt3 and Kit, as well as oncogenic 
mutations in N- and K-Ras (Brandts et al, 2007a). The second classes of mutations, 
termed class II mutations, involve  myeloid transcription factors and impair the 
differentiation of leukemic blasts. Important examples are the  recurrent balanced 
translocations identified in AML, such as the translocation between chromosomes 8 
and 21 (t(8;21) leading to the fusion protein AML1-ETO, the t(15;17) leading to 
PML/RARα, as well as MLL fusion proteins (Kelly and Gilliland, 2002a).  
Mouse models have demonstrated that both class I and class II mutations cooperate 
in the development of AML  (Brandts et al, 2007b;Kelly and Gilliland, 2002b). 
Furthermore, data from AML patients confirm that class I and class II mutations often 
occur simultaneously.  
Among the class I mutations, activating mutations in receptor tyrosine kinases 
(RTKs) have been extensively studied (Stirewalt and Radich, 2003).  
 
1.3  Receptor tyrosine kinases (RTKs) 
RTKs are cell surface signaling molecules and are often mutated in human cancers 
(Blume-Jensen and Hunter, 2001a). The Human Genome Project has determined 
that approximately 20% of human genes encode proteins which are involved in signal Introduction 
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transduction. These proteins are transmembrane receptors, G-protein subunits and 
signal generating enzymes. More than 520 protein kinases and 130 protein 
phosphatases are known to date (Blume-Jensen and Hunter, 2001b). Based on their 
catalytic specificity for tyrosine or serine/threonine residues, these kinases are 
subdivided into tyrosine kinases and serine/threonine kinases. To date, around 90 
human tyrosine kinases have been reported. Of, 58 encode for RTKs and 32 encode 
cytoplasmic, non-receptor protein tyrosine kinases (PTKs)  (Figure 2). RTKs are 
divided into 20 subfamilies(Blume-Jensen and Hunter, 2001b). 
 
 
 
Figure 2. Human receptor tyrosine kinases. The prototypic receptor for each family is indicated 
above the receptor, and the known members are listed below. Abbreviations of the  prototypic 
receptors: EGFR, epidermal growth factor receptor; InsR, insulin receptor; PDGFR, platelet-derived 
growth factor receptor; VEGFR; vascular endothelial growth factor receptor;FGFR, fibroblast growth 
factor receptor; KLG/CCK, colon carcinoma kinase; NGFR, nerve  growth factor receptor; HGFR, 
hepatocyte growth factor receptor, EphR, ephrin receptor; Axl,  a Tyro3 PTK; TIE, tyrosine kinase 
receptor in endothelial cells; RYK, receptor related to  tyrosine kinases; DDR, discoidin domain 
receptor; Ret, rearranged during transfection; ROS, RPTK expressed in some epithelial cell types; 
LTK, leukocyte tyrosine kinase; ROR, receptor orphan; MuSK, muscle-specific kinase; LMR, Lemur. 
Other abbreviations: AB, acidic box; CadhD, cadherin-like domain; CRD, cysteine-rich domain; DiscD, 
discoidin-like domain;  EGFD, epidermal growth factor-like domain; FNIII, fibronectin type III-like 
domain; IgD, immunoglobulin-like domain; KrinD, kringle-like domain; LRD, leucine-rich domain. The 
symbols 򲐀 and 򲐀 denote distinct RPTK subunits. RPTK members in bold and italic type are implicated 
in human malignancies. An asterisk indicates that the member is devoid of intrinsic kinase activity 
adopted from (Blume-Jensen and Hunter, 2001b). 
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1.3.1  Activation of RTKs 
RTK signaling is initiated by binding of its respective ligand. Upon ligand binding, 
RTKs undergo dimerization, followed by tyrosine autophosphorylation of the receptor 
subunits. In the unstimulated state, the activation loop of the RTK occludes substrate 
tyrosine binding to the active site. In the presence of ligand, one or several tyrosine 
residues of the activation loop become phosphorylated in trans  by the dimeric 
receptor partner (Figure 3)  (Blume-Jensen and Hunter, 2001a). This leads to the 
repositioning of the activation loop away from the active site and allows substrate 
access. The  importance of this mechanism is underlined by several examples of 
oncogenic mutations in the activation loop which cause constitutive RTK activation 
(Blume-Jensen and Hunter, 2001a). Once the RTK is autophosphorylated, 
cytoplasmic signaling molecules having Src homology-2 (SH2) and protein tyrosine 
binding domains bind to the RTK, activating specific signaling cascades. 
 
 
Figure 3. RTK activation. RTK kinase activity is tightly repressed in the unstimulated state (left). The 
activation and catalytic loops exist in an equilibrium between a substrate-precluding (blue) and 
substrate-accessible (green) conformation. In addition, the juxtamembrane region (orange) and C-
terminal region (red) might interfere with the conformation of the N-terminal kinase lobe ('N') and/or 
substrate access. Ligand-induced receptor dimerization and tyrosine autophosphorylation result in 
relief of the inhibitory constraints exerted by the activation loop, and the juxtamembrane and C-
terminal regions (right). Adopted from (Stirewalt and Radich, 2003) Introduction 
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It has been shown that more than half of known human RTKs are found to be 
mutated or overexpressed in human malignancies  (Blume-Jensen and Hunter, 
2001b). Kit and Flt3 belong to class III RTK sub family, which also includes PDGFRα, 
PDGFRβ, and CSF1R.  
 
1.4  FMS-like tyrosine kinase 3 (Flt3) 
1.4.1  Flt3 receptor expression and activation 
FMS-like tyrosine kinase 3 (Flt3), is a membrane-bound RTK with an important role in 
hematopoiesis. It has 993 amino acids and consists of five immunoglobulin-like 
extracellular domains, a transmembrane domain, a juxtamembrane domain and two 
intracellular tyrosine-kinase domains (TKDs) linked by a kinase-insert domain (Figure 
4)  (Agnes et al, 1994). In human cells, Flt3 is  expressed on lymphoid, myeloid 
progenitor cells (Rosnet et al, 1996), but not on erythroid cells (Gabbianelli et al, 
1995), megakaryocytes (Ratajczak et al, 1996) and mast cells (Hjertson et al, 1996) . 
Flt3 mRNA can be detected in lympho-hematopoietic organs, such as liver, spleen, 
thymus and placenta, but this may be due to contamination with hematopoietic cells 
(Rosnet et al, 1993).  
Flt3 receptor is activated by binding of its ligand called Flt3 ligand (FL). FL is not only 
expressed in hematopoietic organs such as spleen, thymus, peripheral blood and 
bone marrow but also in the prostate, ovary, kidney, lung, colon, small intestine, 
testis, heart and placenta. Upon binding of FL to the Flt3 receptor, Flt3 dimerizes. 
Subsequently, the activation loop is removed from the substrate binding site and the 
receptor becomes autophosphorylated in trans (Figure 4) (Turner et al, 1996;Weiss 
and Schlessinger, 1998).  Flt3 receptor upon activation activates several signaling 
pathways (MAP and PI-3-Kinase pathways). Later, activated Flt3 is endocytosed and 
degraded in order to terminate the signaling. 
 Introduction 
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Figure 4.  Structure and activation of wild-type Flt3. Transcription of the Flt3 gene produces Flt3 
mRNA, which is translated to Flt3 protein. Flt3 contains five extracellular immunoglobulin-like domains 
(E), a transmembrane domain (TM), a juxtamembrane domain (JM) and two tyrosine-kinase domains 
(K) that are linked through the tyrosine-kinase insert (KI). Cytoplasmic Flt3 undergoes glycosylation 
(G), which promotes localization of the receptor to the membrane. Wild-type Flt3 remains as a 
monomeric, inactivated protein on the cell surface until Flt3 ligand (L), probably in a dimeric form, 
binds the receptor and induces receptor dimerization. Flt3 dimerization promotes phosphorylation (P) 
of the tyrosine-kinase domains, thereby activating the receptor and downstream effectors. The 
dimerized receptors are quickly internalized and degraded. Adopted from (Stirewalt and Radich, 2003) 
 
1.4.2  Flt3 mutations 
The most commonly occurring Flt3 mutations are known as Flt3 internal tandem 
duplication (Flt3-ITD) and they occurs as a result of an internal tandem duplication 
(ITD) in exons 14 and 15 (previously known as exons 11 and 12). ITD mutations 
account for 15–35% of patients with AML (Abu-Duhier et al, 2000;Meshinchi et al, 
2001;Schnittger et al, 2002;Thiede et al, 2002)  and 5–10% of patients with 
myelodysplasia  (Horiike et al, 1997). The other most common Flt3 mutation is a 
missense point mutation in exon 20 of the TKD. These mutations occur in AML (5–
10%), MDS (2–5%) and ALL (1–3%) patients (Thiede et al, 2002;Yamamoto et al, 
2001;Yokota et al, 1997). Flt3-ITD and Flt3-TKD have been shown to confer factor 
independent growth to the myeloid cell lines and involved in deregulated signaling 
pathways (Choudhary et al, 2005).  
 Introduction 
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1.5  Kit 
1.5.1  Kit structure 
Kit is a class-III RTK and a cellular homolog of v-Kit oncogene, which was identified 
in 1986 as the transforming gene in the Hardy-Zuckerman 4 feline sarcoma virus 
(HZ4-FeSV) (Besmer et al, 1986;Yarden et al, 1987). Kit protein is encoded by W 
locus of mice. “Loss-of-function mutations” have been reported at the W locus. In 
mice, complete loss of Kit expression (homozygous) results death in utero or 
prenatally, and it is likely because of severe anemia. In the heterozygous state, mice 
suffer from anemia, pigmentation defects and reduced fertility (Edling and Hallberg, 
2007;Kitamura and Hirotab, 2004;Lennartsson et al, 2005). Kit has an extracellular 
(EC) domain which consists of five immunoglobulin (Ig)-like domains, a single 
transmembrane domain and an intracellular tyrosine kinase domain, which splits into 
two by an insert region (Figure 5) (Edling and Hallberg, 2007;Kitamura and Hirotab, 
2004;Lennartsson et al, 2005). Studies have shown that the first three N-terminal Ig-
like domains of Kit are involved in ligand binding.  
   
                                           
 
Figure 5. Schematic illustration of the Kit receptor. The receptor is drawn to indicate the domain 
structure of Kit. Phosphorylated tyrosine residues (in black) in the human Kit and their number are 
indicated. The corresponding numbers in the murine receptor are designated in parenthesis. Activating 
mutations are shown in red. Abbreviation: Ig, immunoglobulin. Adopted from (Lennartsson et al, 2005) 
 Introduction 
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1.5.2  Stem cell factor  
The product of the steel locus (SL) was shown to be the Kit receptor ligand also 
known  as stem cell factor (SCF). SCF is a heavily glycosylated transmembrane 
protein. The active form of SCF is a non-covalently associated dimer. Kit signaling is 
important for the normal hematopoiesis, gametogenesis and melanogenesis 
(Lennartsson et al, 2005). 
 
1.5.3  Kit expression 
Hematopoietic stem cells express Kit, suggesting an important role of Kit in primitive 
hematopoiesis (Simmons et al, 1994). Kit is also expressed on myeloid, erythroid, 
megakaryocytic progenitor cells (Lennartsson et al, 2005). During hematopoietic cell 
differentiation, Kit expression is usually lost, but mast cells retain this RTK. SCF 
supports proliferation, survival and maturation of mast cells  and enhances 
chemotaxis and adhesion of mature mast cells (Oliveira and Lukacs, 2003). “Loss-of-
function mutations” of Kit cause deficiency of mast cells. Kit expression is observed 
on lymphoid progenitors, but not on differentiated lymphocytes (Lennartsson et al, 
2005).  
 
1.5.4  Kit mutations 
“Loss-of-function mutations” in Kit protein are associated with autosomal-dominant 
piebaldism  which involves deafness, megacolon and abnormalities in pigmentation 
of skin and hair (Spritz, 1994). “Gain-of-function mutations” in Kit are often associated 
with gastrointestinal stromal tumors (GISTs), mastocytosis and AML (Edling and 
Hallberg, 2007;Kitamura and Hirotab, 2004;Lennartsson et al, 2005). GISTs accounts 
for  less  than  1%  of  all  the  gastrointestinal  (GI)  tract  tumors.                                                                                                                                                                                                
Most of the GIST patients (approximately  90%), express Kit and many of them 
contain activating mutations in the juxtamembrane domain (JMD). Specifically, 
exon11 mutations account for 57%-71% of the GIST patients. In rare cases, 
mutations in the kinase domain are observed (GIST patients).  Mutations in the JMD 
abrogate, the negative regulatory function of JMD and responsible for the constitutive 
activation of the Kit receptor (Ma et al, 1999).  
Normal wild type Kit (80%-90%) is over-expressed on blasts of most AML patients 
and in some cases of CML blast crisis (Heinrich et al, 2002). In contrast, Kit is rarely 
expressed on the leukemic blasts of lymphoid origin. Most of them are deletions and Introduction 
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insertions in exon 8 that code for the Kit extra cellular domain (Gari et al, 1999). 
Mutations at codon 416 was observed and this is believed to be “gain-of-function 
mutation” (Gari et al, 1999).  Kit mutations (D816Y or D816V), at codon 816 in the 
kinase domain are also observed in the patients of core binding factor leukemias 
(Beghini et al, 2000a;Paschka et al, 2006a). 
 
1.6  Kit signaling 
It is known that SCF/Kit signaling play a role in proliferation, 
maturation/differentiation, and survival. Upon binding of SCF to the Kit receptor, Kit 
undergoes dimerization, followed by transphosphorylation of two tyrosine residues 
(Y568 and Y570) in the auto inhibitory juxtamembrane segment (Figure 5) (Hubbard, 
2004;Mol et al, 2004). This leads to a conformational modification of the activation 
loop and results in the intrinsic tyrosine kinase activity of the Kit (Figure 5) (Mol et al, 
2004). Finally, activated Kit autophosphorylates the other tyrosine residues that serve 
as docking sites for signal transduction molecules containing Src homology 2 (SH2) 
or phospho tyrosine binding domains (Figure 6). 
 
1.7  Activation of signal transduction pathways  
Stimulation of the Flt3 and Kit receptor with their respective ligands activates several 
downstream signaling pathways (Figure 6).  
 
1.7.1  MAP kinase pathway  
Kit and Flt3 have been shown to activate the MAP (mitogen activated protein) kinase 
pathway (Choudhary et al, 2005;Edling and Hallberg, 2007). In short, the MAP kinase 
pathway involves, activated receptor recruits and activates the Grb2 -SOS complex. 
This complex activates RAF kinase via Ras. RAF kinase activates MEK by 
phosphorylation. MEK activates a mitogen-activated protein kinase (MAPK). MAPK 
also called as extracellular signal regulated kinase (ERK) and microtubule-associated 
protein kinase (MAPK). MAPK activates several transcription factors, including c-
myc, CREB and c-Fos. Map kinase pathway is involved in a wide range of cellular 
functions  like proliferation (Yoon and Seger, 2006).  
        Introduction 
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Figure 6. Overview of the signaling pathways activated upon SF ligation to Kit. Ras is activated 
via the adaptor complex Sos/Grb2/Shc, Ras in turn activates the MAPK pathway (indicated in red). 
PLCγ leads to activation  of PKC (grey).  Activation  of Cbl via  APS  leads to  downregulation of the 
receptor (grey). Src, Shp and Gab2 are involved in activating Rac in mast cells, which  results in 
activation of the transcription factor c-Jun (blue). PI-3-Kinase binds the receptor directly and activates 
PKB via phospholipids at the membrane, which subsequently leads to inactivation of pro-apoptotic 
proteins (green). Adopted from (Edling and Hallberg, 2007) 
 
1.7.2  PI-3-Kinase pathway  
The other signaling pathway activated upon ligand binding of Flt3 and Kit is PI-
3(phosphoinositide-3)-Kinase  (Choudhary et al, 2005;Vosseller et al, 1997). PI3-
Kinase is a heterodimeric complex composed of the p85 regulatory and the p110 
catalytic subunit. Activated PI-3 kinase phosphorylates phosphatidylinositol-4, 5-
bisphosphate (PtdIns4, 5P2), and subsequently generates PtdIns (3, 4, 5) P3.  The 
lipid intermediate PtdIns (3, 4, 5) P3, activates Akt (protein kinase B). PI3-kinase 
binds to tyrosine residue 721 in the kinase insert of human Kit (Figure 5-6). PI3-
kinase has been shown to be involved in DNA synthesis, cell survival, membrane 
ruffling, chemotaxis, receptor and vesicular trafficking (Fresno Vara et al, 
2004;Linnekin, 1999).  
 
1.7.3  JAK/STAT pathway  
The Janus kinases (JAKs) are tyrosine kinases and localized in the cytoplasm. They 
are rapidly activated by ligand binding to RTKs or cytokine receptors. JAKs activate 
signal transducers and activators of transcription (STAT). STATs are transcription Introduction 
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factors and have  a  DNA binding domain, SH2 domain  and a C-terminal 
transactivation domain. JAKs, activate cytoplasmic STATs by phosphorylation, which 
undergo dimerization through the SH2 domain and subsequent translocation to the 
nucleus. STATs control expression of responsive genes by binding to their 
promoters. Phosphorylation of serine residues in STATs (at least 1, 3, and 5), 
regulate their transcriptional activity. SCF activates JAK-STAT pathway (Weiler et al, 
1996). JAK2 constitutively associates with Kit and Flt3 and are transiently activated in 
response to FL/SCF (Linnekin et al, 1996). JAK2 siRNA studies suggest that it is 
important for SCF-induced proliferation (Linnekin et al, 1996).  FL/SCF stimulation 
leads to the association of STAT1, STAT5A, and STAT5B with Flt3 and Kit and 
become tyrosine phosphorylated (Brizzi et al, 1999;Zhang et al, 2000). SCF, but not 
FL activates STAT3 by serine phosphorylation (Lennartsson et al, 2005;Zhang et al, 
2000). 
 
1.8  Src family tyrosine kinases (SFKs) 
The Src family tyrosine kinases (SFKs) are named after its prototypic family member 
c-Src, which is a cellular homolog of v-Src (the transforming protein of Rous sarcoma 
virus). SFKs play a role in a wide variety of cellular functions including adhesion, 
chemotaxis, survival, proliferation and protein trafficking. Src family members, such 
as Src, Yes and Fyn, are expressed ubiquitously, whereas expression of Lck, Hck, 
Fgr, Lyn and Blk is restricted to particular cell types (Abram and Courtneidge, 2000). 
SFKs have an  N-terminal sequence, which is responsible for myristoylation and 
palmitoylation, both of which mediate anchoring to the plasma membrane. SFKs also 
contain a SH3 domain, a SH2 domain and a tyrosine kinase domain. In general, the 
kinase activity of SFKs is tightly controlled through intermolecular interactions (Figure 
7). 
         Introduction 
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Figure 7. Src activation. Left: c-Src kinase activity is tightly repressed in the unstimulated state. The 
SH2 domain interacts with phospho-Tyr 527 in the C terminus and the SH3 domain with the 
polyproline type II helix in the linker region between the SH2 and kinase domain. This causes 
misalignment of residues that are critical for kinase activity. Right: binding of molecules to the SH2 or 
SH3 domain and/or dephosphorylation of phospho-Tyr527 by phosphatases  relieves the inhibitory 
constraints on the kinase, resulting in its activation. Adopted from (Blume-Jensen and Hunter, 2001b). 
 
These SH2 and SH3 intermolecular interactions inhibit kinase activity.  SFKs can be 
activated by dephosphorylation of Tyr527, through by binding of its SH2 domain to 
the  autophosphorylated tyrosine residues in the ligand-stimulated RPTKs, or by 
binding of the SH3 domain to Pro-X-X-Pro motifs present in the target molecules. 
Phosphorylation at tyrosine 416, (present in the activation loop) also stabilizes the 
active conformation of SFKs. Kit and Flt3 activates SFKs by recruiting them to the 
phosphorylated tyrosine residues 568 and 570 (Y589 and Y599 in the case of Flt3) 
(Heiss et al, 2006;Lennartsson et al, 1999;Timokhina et al, 1998). Kit activated SFKs 
play role in ligand-induced internalization of Kit and chemotaxis in primary 
hematopoietic cells. Furthermore, studies indicate that, Kit receptor lacking SFK 
binding site (Kit Y567F) resulted in decreased autophosphorylation of the receptor 
and  defects in mast cell and lymphocyte development (O'Laughlin-Bunner et al, 
2001;Ware et al, 1997). 
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1.9  Regulation of Flt3 and Kit 
After activation, Kit and Flt3 are degraded via the E3 ubiquitin–protein ligase Cbl.  Cbl 
promotes the  degradation of Kit  and Flt3  proteins  by ubiquitinating the receptors 
(Sargin et al, 2007;Zeng et al, 2005). Furthermore, Kit activity is down regulated via 
Shp1 (SH2 domain-containing phosphatase 1) protein, which is a cytosolic 
phosphotyrosyl phosphatase.  Studies indicate that Kit binds to Shp1 directly, which 
dephosphorylates  the receptor, or indirectly by dephosphorylating other receptor-
associated protein-tyrosine kinases (Kozlowski et al, 1998). Recent data suggests 
that protein kinase C (PKC) can downregulate Kit activity by phosphorylating Kit on 
specific serine residues leading to negative regulation of Kit activation (Edling et al, 
2007). In summary, the signaling pathways downstream of the Kit and Flt3 receptor 
are required for controlling proliferation, survival and other functions in early 
hematopoietic cells.   
 
1.10  Ubiquitination 
Ubiquitination occurs in a multistep process. Initially, the E1 ubiquitin-activating 
enzyme forms a thioester bond with ubiquitin molecule. Then the ubiquitin molecule 
is transferred to an E2 conjugase, which has some substrate specificity. Ubiquitin-
conjugating enzymes interact with the RING fingers of Cbl proteins (Pickart, 2001). 
Finally, the transfer of ubiquitin from the E2 molecule to target protein is catalysed by 
an E3 ligase.  E3 ligases are of mainly two types (RING or HECT). E3 ligases of the 
RING type form no covalent bond between ubiquitin and ligase. E3 ligases of the 
HECT type form  a covalent bond between ubiquitin and E3 ligases.  E3 ubiquitin 
ligases are the proteins that have the ability to transfer ubiquitin molecules to the 
target protein. Cbl proteins are RING finger type E3 ligases. TKB and RING domain 
are interconnected by a short linker sequence which is also crucial for ubiquitin ligase 
activity of Cbl. Mutations in linker region render Cbl transforming (Thien et al, 2001). 
TKB and RING facilitate ubiquitination and degradation of activated PTKs 
(Swaminathan and Tsygankov, 2006). TKB domain confers substrate specificity 
where as the RING finger helps in bringing an E2 ubiquitin-conjugating enzyme. 
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1.11 Cbl (Casitas B-lineage lymphoma) 
1.11.1 Cbl homologues and structure 
v-Cbl was the first member of the Cbl family proteins and was cloned from the Cas 
NS-1 retrovirus in 1989. V-Cbl  induces pre-B-cell lymphomas and myelogenous 
leukemia in mice (Langdon et al, 1989a). Subsequently, it was noticed that v-Cbl is a 
truncated form of a cellular homologue known as c-Cbl (Langdon et al, 1989b). The 
full-length  form  of Cbl  consists of an N-terminal tyrosine-kinase-binding  (TKB) 
domain, a RING (interesting new gene) finger motif, a proline-rich region and a c-
terminal ubiquitin-associated (UBA) domain and leucine zipper (LZ) motif (Figure 8). 
Cbl has been shown to have three mammalian homologues c-Cbl, Cbl-b (Keane et 
al, 1995) and Cbl-c (Figure 8) (Keane et al, 1999;Kim et al, 1999). C-Cbl and Cbl-b 
are expressed ubiquitously and have orthologues in Drosophila melanogaster and 
Caenorhabditis elegans.  Cbl-c is the shorter isoform of Cbl and mainly expressed in 
epithelial cells. From here onwards, c-Cbl is termed Cbl, unless indicated. 
 
 
 
Figure 8. Cbl protein family in mammals.  All Cbl proteins share a high level of sequence 
conservation between their TKB, linker (L) and RING finger (RF) domains. Cbl and Cbl-b have 
extensive proline-rich regions (black) in their C-terminal halves that mediate interactions with 
numerous SH3-domain-containing proteins. The TKB domain is composed of three interacting regions 
comprising a four-helix bundle (4H), a calcium-binding EF hand and a variant SH2 domain that is 
connected to the RING finger by a short linker domain. The PR domain in the C-terminus of Cbl and 
Cbl-b refers to a PX(P/A)XXR motif that binds SH3 domains of the CIN85/RUK (regulator of ubiquitous 
kinase)/CD2AP (C2-associated protein) family of proteins. The UBA domain at the C-terminus of Cbl, 
Cbl-b and D-Cbl (long) refers to a region with homology to UBA domains. Conserved tyrosine residues 
are shown in purple. Adopted from (Thien and Langdon, 2005a) 
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The tyrosine kinase-binding (TKB) domain is homologous to v-Cbl. TKB domain     
contains a four-helix bundle (4H), a calcium-binding EF hand and a modified SH2 
domain.  The  TKB domain binds to phospho-tyrosine residues in multiple tyrosine 
kinases (Meng et al, 1999a). The preferred sequence for binding of TKB to the target 
molecules is (N/D) XpY(S/T) XXP. The RING finger domain is a highly conserved 
region of Cbl, which plays an important role towards conferring an E3 ubiquitin ligase 
activity to the Cbl (Joazeiro et al, 1999;Levkowitz et al, 1999).  
 
1.11.2 RTK regulation by Cbl 
Activated RTKs mediate downstream signaling and duration of their downstream 
response  is  tightly controlled. Receptor  deactivation takes place by 
dephosphorylation of the receptor or by removing the receptors from the membrane 
by endocytosis, followed by degradation or recycling. Cbl plays an important role in 
the RTK ubiquitination. Epidermal growth factor receptor (EGFR) trafficking and 
degradation by Cbl is one of the best-studied mechanisms in RTK degradation. RTK 
degradation is a multistep process and was described initially in C. elegans. The Cbl 
orthologue SLI-1 regulates the signaling downstream of LET-23 receptor (EGFR 
orthologue)  (Jongeward et al, 1995;Sternberg et al, 1995;Yoon et al, 1995). RTK 
degradation involves the following steps. Upon binding of EGFR with its ligand EGF, 
the receptor is dimerized and activated. Autophosphorylation of the receptor creates 
docking sites for suitable proteins and initiates  the formation of a multiprotein-
receptor complex. Grb2 (growth-factor-receptor bound-2) is one of the first proteins to 
be recruited to the complex. Grb2 binds to proline-rich region of the Cbl and recruits it 
to the complex (Fukazawa et al, 1996;Jiang et al, 2003). During EGFR activation, 
tyrosine 1045 becomes  phosphorylated,  creating a  direct Cbl binding site. As a 
consequence, the Cbl molecule mediates the ubiquitination of EGFR. Following the 
ubiquitination  of  the  EGFR by Cbl, EGFR is recruited to clathrin-coated pits by 
adaptors, such as Eps15. These adaptors possess ubiquitin-binding domains and 
motifs that bind to clathrin adaptors (AP2) (de Melker et al, 2004a;de Melker et al, 
2004b). AP2 complexes help in the formation of clathrin-coated vesicles. They 
eventually fuse with internal vesicles to form an early endosome (Figure 9). They 
progress to become multi-vesicular bodies. In multi-vesicular bodies, receptors are 
sorted for either recycling or degradation, which takes place in the lysosomes.  
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Figure 9. Ubiquitination in receptor endocytosis and degradation. Monoubiquitin (orange circles) 
appears to carry both internalization and degradation signals. Depicted is the current view on how 
interactions between monoubiquitinated cargo [e.g. EGFR] and sorting Ub-receptors [e.g. Eps15, 
hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs; blue oval) and tumor-susceptibility 
gene product 101 (TSG101; purple oval)] might control RTK downregulation.  
 
Cbl has been shown to down regulate several RTKs, including  platelet-derived 
growth factor receptor (PDGFR), colony-stimulating factor (CSF-1) receptor, 
hepatocyte growth factor (HGF) receptor (Met), neurotrophin receptor (p75NTR), Kit 
(Zeng et al, 2005), vascular endothelial growth factor (VEGF) receptor (Flk-1), Flt-1 
macrophage-stimulating protein (MSP) receptor, glial cell-derived neurotrophic factor 
(GDNF)  receptor (Ret), fibroblast growth factor receptor  (FGFR), and the  insulin 
receptor (IR) (Fukazawa et al, 1996;Jiang et al, 2003;Swaminathan and Tsygankov, 
2006). Furthermore, Cbl has also been shown to down-regulate non-receptor protein 
tyrosine kinases including Syk, Fyn, Lck, Hck, Lyn, and c-Abl  (Kyo et al, 
2003;Yokouchi et al, 2001). 
 
1.11.3 Phosphorylation of Cbl 
Cbl is phosphorylated by a wide variety of molecules. Cbl is a substrate for oncogenic 
PTKs such as Bcr-Abl, v-Abl and v-Src (Andoniou et al, 1994a;Andoniou et al, 1996). 
T-cell receptor/CD3 (TCR/CD3), B-cell receptor (BCR), as well as other multi chain 
immune recognition receptors induce Cbl phosphorylation upon activation (Cory et al, 
1995). Furthermore, several RTKs, such as Kit, EGFR, and PDGFR, CSF-1, and 
insulin receptor  have been shown to induce Cbl phosphorylation (Bonita et al, 
1997a;Kanagasundaram et al, 1996). Thus, Cbl becomes phosphorylated in Introduction 
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response to cytokines such as, thrombopoietin (TPO), erythropoietin (EPO), 
interleukin  3  (IL-3), IL-4 and IFN-α  (Barber et al, 1997;Gesbert et al, 1998).  Cbl 
tyrosines 700, 731 and 774 have been identified as important sites of c-Cbl. These 
are phosphorylated by non-receptor PTKs (Andoniou et al, 1994a;Feshchenko et al, 
1998). It appears that all non-receptor PTKs phosphorylate Cbl at these sites, 
showing that no significant individual specificity. When Cbl is phosphorylated by non-
receptor PTKs at tyrosine 731, it recruits and activates PI-3-kinase  (Hunter et al, 
1999a). 
 
1.11.4 Cbl as a multivalent adaptor protein 
Numerous reports have shown that Cbl acts as multivalent adaptor protein. Cbl is 
rapidly phosphorylated upon several external or oncogenic signals and is able to 
associate with a wide range of intracellular signaling partners. PTB domain of Cbl 
interacts with phosphorylated protein tyrosine kinases, such as RTKs, Src and Zap70 
(Meng et al, 1999b;Sanjay et al, 2001;Schmidt and Dikic, 2005). The RING domain 
mainly interacts with components of the ubiquitin system including E2 proteins 
(UbcH7) and sprouty proteins  (Wong et al, 2002). N-terminal sequences of Cbl 
proteins are typically followed by proline-rich regions, which appear to mediate 
binding with SH3 domain proteins. Grb2, which is an adaptor protein constitutively, 
associates with Cbl via its amino terminal SH3 domain (Meng et al, 1999b;Sanjay et 
al, 2001;Schmidt and Dikic, 2005). Furthermore, several proteins such as Nck, p85, 
Cap, ArgBp2, CIN85, CMS, SFKs, Abl and CrkL have been shown to bind proline rich 
regions of the Cbl (Dikic et al, 2003). Thus, Cbl can integrate several signaling 
pathways and act as a scaffold. 
 
1.11.5 Cbl mutations in cancer 
Mutations in the tyrosine kinase binding domain, linker,
 or RING finger domain of Cbl 
result in deregulation of RTKs (Andoniou et al, 1994b;Peschard et al, 
2001a;Peschard and Park, 2003).
  Most of these mutants are thought to act in a 
dominant-negative
 manner by competing with the wild-type receptor. v-Cbl, a mutant
 
form of Cbl, has been found in Cas NS-1 retrovirus as a fusion
 protein. It lacks the C-
terminus part of wild-type Cbl and
 can induce pre–B-cell lymphomas and leukemia in 
mice  (Langdon et al, 1989b).
  Cbl-70Z  was  a 17-amino acid deletion mutant  and 
isolated from 70Z/3 mouse
 pre–B-cell lymphoma (Andoniou et al, 1994b) (deletion Introduction 
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occurs between amino acids 366 and 382, at the boundary
 of the linker and RING 
finger domain).  
We recently reported the first
 Cbl oncogenic mutation in a single case of 150 de novo 
AML patients, Cbl-R420Q, and analyzed the role
  of this mutant in Flt3 signaling 
(Sargin et al, 2007). Cbl-R420Q and Cbl-70Z
 confer IL-3–independent growth
 to the 
32Dcl3 cell line in the presence of wild-type Flt3 receptor (Sargin et al, 2007). C-Cbl
 
physically interacts with Flt3 and is tyrosine phosphorylated
 in the presence of Flt3-
ligand (FL). Overexpression of a dominant-negative
 form of c-Cbl (Cbl-70Z) inhibited 
FL-induced Flt3 ubiquitination and internalization, indicating involvement of c-Cbl in 
Flt3
  signaling.  Cbl-R420Q also inhibited
  Flt3 internalization and ubiquitination. In 
addition, the mutant
  Cbl proteins altered the amplitude and duration of Flt3-
dependent
 signaling events.   
Subsequently, several additional mutations have been found in Cbl and Cbl-b (Abbas 
et al, 2008;Dunbar et al, 2008;Grand et al, 2009;Loh et al, 2009;Makishima et al, 
2009;Sanada et al, 2009;Sargin et al, 2007).  In a separate  study, missense 
mutations in exon 8 were reported in 3 out 12 AML cases (Caligiuri et al, 2007a). 
Further studies have shown Cbl exon 8 splice variant mutations associated with CBF 
leukemias (Abbas et al, 2008;Reindl et al, 2009). Several reports have also shown 
somatic CBL mutations in the critical linker and ring finger domains (exons 8 and 9). 
(Makishima et al, 2009;Sanada et al, 2009). These mutations are frequent in myeloid 
malignancies, particularly (but not exclusively) in myelodysplasia/myeloproliferative 
neoplasms (MDS/MPN) with acquired uniparental disomy (aUPD) at chromosome 
11q  (Dunbar et al, 2008;Grand et al, 2009;Loh et al, 2009).  
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2  Aims of the study  
In AML, Flt3 and Kit are frequently mutated, leading to constitutive activation. 
However, Flt3 and Kit are not mutated in the majority of AML patients, but found 
highly expressed on the cell surface of myeloids blasts. The mechanisms leading to 
Flt3 and Kit overexprssion are unknown. The magnitude
  and kinetics of RTKs 
activation is tightly regulated which determines the quality and quantity of the biologic 
response.
 Termination of RTK signaling occurs by endocytosis and subsequent
 RTK 
degradation or recycling. Cbl proteins have been shown to
 be central players in the 
Ubiquitination, internalization and endocytosis of RTKs, but their role for Flt3 and Kit 
in myeloid transformation has not been determined. During this thesis work, we were 
specifically interested in the following questions: 
 
•  Do Cbl mutants synergize with Kit receptor to give cytokine  independent 
growth in a myeloid cell line system, as an indication for transformation? 
•  Do Cbl mutants inhibit the ubiquitination and endocytosis of the activated Kit 
receptor? 
•  Is kinase activity of Kit and Flt3 required in the context of Cbl mutants? 
•  Do Cbl mutants alter the quality and quantity of Kit receptor signaling? 
•  Do Cbl mutants cause a hematological disease in vivo? 
•  What is the functional consequence of over-expressed Kit receptor?  
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3  Materials and methods  
3.1  Reagents and antibodies  
Recombinant human Flt3 ligand (FL), murine SCF and murine IL-3 were purchased 
from PeproTech (Rocky Hill, NJ). Polyclonal rabbit anti-phospho-Erk-1/2, anti-
phospho-Kit (Tyr-719), anti-phospho-Src family (Tyr-416) and anti-phospho-Akt 
antibodies were obtained from Cell Signaling Technology (Beverly, MA). The 
antibodies for Kit, Flt3, HA-tag, and signal transducer and activator of transcription 
5a/b (anti-STAT5a/b) were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). The mouse monoclonal anti-c-Cbl antibody was obtained from BD Biosciences 
(San Jose, CA). Antibodies for anti-Erk-1/2, and anti-phospho-STAT5a/b were 
purchased from Upstate Biotechnology (Lake Placid, NY). The mouse monoclonal 
anti-actin antibody was purchased from Sigma (Taufkirchen, Germany). 
Phycoerythrin (PE)-labeled murine anti-Kit antibody was obtained from BD 
Pharmingen (San Jose, CA). The Src family inhibitors PP-1 and PP-2 were 
purchased from Calbiochem (San Diego, CA). The Horseradish peroxidase 
conjugated goat-anti-mouse, goat-anti-rabbit, and red-X conjugated goat-anti-mouse 
antibodies were obtained from Jackson Immunoresearch (West Grove, PA).  
 
3.2  Methods 
3.2.1  Generation of plasmid constructs  
pAL-Kit wt (murine and human hybrid) was a kind gift of Dr. Klaus-Michael Debatin. 
pCDNA3 Kit WT and pCDNA3 Kit-D790N (Kit-KD) were generated by sub cloning 
from pAL-Kit WT and pAL-Kit-KD using EcoRI and Not1 restriction enzymes. pMY 
Cbl wt, pMY Cbl-R420Q, pMY Cbl-70Z were generated by sub cloning from pSRα 
vector based plasmids using Not1 restriction enzyme. HA (Hemagglutinin) tagged Cbl 
constructs were sub-cloned to pMY vector using BamH1 restriction enzyme from 
pSRα based plasmids.  
 
3.2.2  Site-directed mutagenesis  
Site-directed mutagenesis was performed using the Quick-Change site directed 
mutagenesis Kit (Stratagene, Amsterdam, Netherlands) according to the 
manufacturer’s instructions. For generating kinase dead Kit (Kit-D790N), aspartic 
acid 790 of Kit-WT was replaced with asparagine. Mutation was confirmed by 
sequencing.  Materials and methods 
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3.2.3  Cell lines  
The IL-3-dependent murine myeloid cell line 32Dcl3 (subsequently referred to as 
32D) was cultured in RPMI 1640, supplemented with 10% WEHI-conditioned medium 
as a source of IL-3, 10% fetal calf serum (FCS) and antibiotics as described. COS-7 
cells were cultured in Dulbecco modified Eagle medium (Invitrogen, Karlsruhe, 
Germany). Cells were maintained in a humidified incubator at 37°C and 5% CO2.  
 
3.2.4  Retrovirus preparation  
Platinum-E (Plat-E) ecotropic packaging cells (Morita et al, 2000) and NIH3T3 cells 
were maintained in Dulbecco modified Eagle medium (DMEM; GIBCO-BRL, 
Karlsruhe, Germany) supplemented with 10% FCS. Plat-E cells were transiently 
transfected using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) with pMY 
(vector alone)/pMY Cbl-R420Q/pMY Cbl-70Z retroviral plasmids. Viral supernatants 
were collected 36 hours post transfection at 12 hours interval, sterile filtered using 
0.45 μM syringe filters and stored at 4°C for short-term storage or snap frozen and 
stored at -80
oC until use. Retrovirus was titered by transduction of 5 × 10
4 NIH3T3 
cells with serial dilutions of retrovirus in the presence of 4 μg/mL polybrene (Sigma, 
Deisenhofen, Germany). Forty-eight-hours after transduction, percentage of infected 
cells were determined by flow cytometric analysis of EGFP expression. The titer was 
calculated by multiplication of the total number of EGFP-positive cells with the dilution 
factor of the retroviral supernatant. We tested for the presence of replication-
competent viral particles by transferring supernatant onto NIH3T3 cells. The NIH3T3 
cells were subsequently analyzed for EGFP expression by fluorescence-activated 
cell scanner (FACS) analysis. 
 
3.2.5  Transduction and transplantation of murine bone marrow 
Murine bone marrow was harvested from female Balb/C donor mice
  4 days after 
injection of 150 mg/kg 5-fluorouracil (Ribosepharm)
 and prestimulated overnight in 
Iscove modified Dulbecco medium/20%
 FCS supplemented with growth factors (10 
ng/mL murine IL-3 [mIL-3],
 10 ng/mL mIL-6, 50 ng/mL mSCF). Cells were transduced 
by 4 rounds
 of spin infection (1200g, 32°C, 90 minutes) every 12 hours
 in retroviral 
supernatant supplemented with growth factors and
  4 µg/mL polybrene (Sigma-
Aldrich). Retroviral experiments
  were performed using the murine stem cell virus-
based retroviral
  construct pMY (Kitamura et al, 2003a). Subsequently, cells were Materials and methods 
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resuspended in Hanks
 balanced salt solution (Sigma-Aldrich) and injected into the
 tail 
vein of lethally irradiated (8 Gy) female Balb/C recipient
 mice. Transplanted animals 
were monitored for signs of disease
  development and by serial measurement of 
peripheral blood counts.
  All procedures were reviewed and approved by the 
University
 of Frankfurt supervisory animal care committee. 
 
3.2.6  Flow cytometric immunophenotyping (FACS analysis) 
Single-cell suspensions of indicated tissue samples were prepared,
 and red blood 
cells of peripheral blood were lysed before analysis.
 Cells were subsequently stained 
with PE-conjugated anti-CD117
  (Kit), anti-CD11b (Mac-1), anti–Gr-1, anti-
CD45R/B220,
  or anti-CD3 antibodies. All antibodies were purchased from BD
 
Biosciences PharMingen. 
 
3.2.7  Histopathology 
Complete necropsies were performed and histopathology examinations were carried 
out on spleen, liver, Bone marrow, Kidney and heart from both Cbl mutants 
transplanted and control mice. Tissue samples were fixed by immersion in 10% 
neutral-buffered formalin, embedded in paraffin, and 5-µm tissue sections were 
stained with hematoxylin and eosin (H&E). Representative images of H&E-stained 
sections were acquired using a microscope digital camera. 
 
3.2.8  Generation of stable cell lines  
For the generation of stable cell lines 32D cells were electroporated with 10 μg of 
pAL Kit WT, pAL Kit-D790N (Kit-KD) or pAL Flt3-K644A (Flt3-KD) together with 1 μg 
of pMAM/BSD (Blasticidin) (Kaken Pharmaceutical, Japan) as selection marker in 0.4 
cm cuvettes at 280 V and 975 μF. After 48hrs of culturing, cells were selected with 15 
μg/mL Blasticidin (Invitrogen, Groningen, Netherlands) in IL-3 supplemented culture. 
In order to generate stable cell lines with Cbl, 32D or 32D cells stably expressing Kit-
WT, Kit-D790N or Flt3-K644A were infected with retroviral supernatants of pMY Cbl-
R420Q, pMY Cbl-70Z or pMY (empty vector). For immunoprecipitation experiments, 
cell lines were transduced with different HA-tagged Cbl retroviral supernatants. 
Green fluorescent protein (GFP) marker was used for the sorting of the transduced 
cells with the help of Flow cytometry. To avoid possible clonal selection, at least 2 
bulk cultures were generated for each cell line.  Materials and methods 
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3.2.9  Analysis of cell growth  
The 32D cells expressing indicating constructs were washed twice with phosphate 
buffered saline (PBS) and re-suspended in RPMI 1640 with 10% FCS alone or 
supplemented with the indicated growth factors or with  the inhibitors Imatinib, 
dasatinib, or Akt inhibitor. Cell viability was determined by Trypan blue exclusion until 
day 3. Cells were seeded at a concentration of 2x10
5 cells/mL.  
 
3.2.10 
3[H]-thymidine incorporation  
A total of 3 × 10
4 32D cells with indicated constructs were starved of IL-3 in 10% FCS 
for  12  hours  and  subsequently  placed  in  200  μl  of  medium  containing  indicated 
cytokines/nothing/15 μM of PP-1/PP-2. After 6 hours of incubation at 37°C with 5% 
CO2,  0.037  MBq  (1  μCi) 
3[H]-thymidine was added to each well  and cells were 
incubated for an additional 15 hours. Cells were harvested on glass fiber filters, and 
emission of the bound DNA was analyzed with a scintillation counter. Experiments 
were repeated at least 3 times. Each data point represents the mean and the 
standard deviation of triplicates from one of at least three independent experiments.  
 
3.2.11 Ubiquitination assays  
For transient expression experiments COS-7 cells were used. For transfection, 
Nanofectin (Q051-005; PAA Laboratories, Cölbe, Germany) was used. Transfection 
was done according to the manufacturer’s protocol. A total of 2 × 10
6 cells were 
seeded in 10-centimeter dish. On the following  day cells were transfected with 
pCDNA3 Kit WT or Kit-KD in the presence or absence of Cbl mutants along with HA 
tagged Ubiquitin (pCMV-HA-Ubiquitin). After 48hrs of transfection, cells were serum 
starved for 12 hours and then stimulated with 50 ng/mL SCF for 10 minutes. 
Subsequently, cells were washed once with ice-cold PBS and lysed with buffer 
containing 50 mM HEPES (pH 7.4), 10% glycerol, 150 mM NaCl, 1% Triton X-100, 1 
mM EDTA, 1 mM EGTA, 50 µM ZnCl2, 25 mM NaF, proteinase inhibitors (Complete; 
Boehringer Mannheim, Germany), 1 µM pepstatin, and 1 mM sodium orthovanadate. 
After incubation on ice for 10 minutes, cell lysates were clarified at 20,000g for 10 
minutes at 4
oC. For immunoprecipitation, the cell lysates were incubated either with 
control rabbit polyclonal serum or with an antibody to Kit overnight and then protein 
A/G-Plus-sepharose beads (Santa Cruz Biotechnology) were added for an additional 
2 hours. The immunoprecipitates were washed 4 times with lysis buffer, resolved by Materials and methods 
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SDS-PAGE, transferred to Immobilon P membranes (Millipore, Bedford, MA) and 
probed either with anti HA (detects exogenous Ubiquitin) or with anti-Kit (an antibody 
that recognizes total Kit present in the cell) or with Cbl antibodies overnight at 4
oC. 
Immunodetection was performed using ECL-Plus (Amersham Pharmacia, Uppsala, 
Sweden). 
 
3.2.12 Immunoprecipitation and Western blot analyses  
32D cells transfected with either Kit-WT or Kit-D790N (Kit-KD) or Flt-3-KD and Cbl 
constructs were washed twice with PBS and starved overnight in the medium 
containing 10% FCS or cells were starved in the medium containing 10% FCS with 
inhibitors PP-1, PP-2,  or dasatinib  for 12hrs. They were then stimulated for 10 
minutes at 37°C with either 50 ng/mL SCF or 1 ng/mL IL-3 or nothing. Cells were 
lysed in RIPA lysis buffer (It has 150 mM NaCl, 1% NP40, 0.5% deoxycholicacid, 
0.1% SDS, 50 mM Tris pH 8, 1μM pepstatin, and 1 mM sodium orthovanadate) or in 
the buffer (which was used for all immunoprecipitation experiments) containing 50 
mM HEPES (pH 7.4), 10% glycerol, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 
mM EGTA, 50 μM ZnCl2, 25 mM NaF, proteinase inhibitors (Complete; Boehringer 
Mannheim, Germany), 1 μM pepstatin, and 1 mM sodium orthovanadate. For the 
immunoprecipitation of HA-tagged proteins, cell lysates were incubated overnight 
with an anti-HA antibody conjugated affinity matrix (Roche, Mannheim, Germany). 
The immunoprecipitates were washed 4 times with lysis buffer, resolved on SDS-
PAGE, and probed with the indicated antibodies overnight at 4°C.  
 
3.2.13 Internalization assays  
Internalization assays were carried out in both 32D and COS-7 cells. For transfection 
of COS-7 cells, nanofectin (Q051-005; PAA Laboratories, Cölbe, Germany) was used 
as a transfection reagent. Transfection was done according to the manufacturer’s 
protocol. 2 × 10
6 cells were seeded in 10-centimeter dish. On the next day, cells were 
transfected with pCDNA3 Kit WT in the presence or absence of Cbl mutants. A total 
of 5 × 10
5 32D or Cos-7 cells expressing Kit-WT alone or in combination with the 
indicated Cbl constructs were washed with PBS and then stimulated with SCF for 0, 
5, 10, and 30 mins. Internalization of the receptor was stopped by placing cells on ice 
and adding ice-cold PBS containing 0.4% sodium azide. After washing, the cells were 
incubated with a PE-labeled anti-Kit antibody for 30 minutes at 4°C. The mean Materials and methods 
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fluorescence intensity of the stained cells was analyzed by flow cytometry using 
CellQuest software (BD Biosciences, Palo Alto, CA).  
 
3.2.14 Clonal growth in methylcellulose  
To analyze clonal growth, 1 mL of a culture mixture containing Iscove’s Modified 
dulbecco medium (IMDM; Life Technologies, Grand Island, NY), 1% methylcellulose, 
and 10% FCS was plated on a 35-mm culture dish in the presence of either with no 
cytokines or with 15μM  PP-2. Stably transfected 32D cells expressing Kit wt/Kit-
KD/Flt3-KD in the presence or absence of Cbl mutants were seeded at a 
concentration of 1x10
3 cells per dish. The assays were carried out in triplicates, and 
colonies were photographed and counted on day 6. The results shown are 
representative of one of at least 3 independent experiments per construct. 
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4  Results 
In order to address the questions outlined in the Aims section (section 2) of this 
thesis, the role of the Cbl mutants Cbl-R420Q and Cbl-70Z in vitro and in vivo was 
analysed.  For many experiments,  we used the  myeloid  32D  cell line,  unless 
otherwise indicated. 
 
4.1  Cbl mutants (Cbl-R420Q and Cbl-70Z) confer ligand-independent growth 
in cooperation with Kit 
4.1.1  Surface expression of Kit receptor 
Firstly, stable 32D cell lines expressing Kit wild-type (WT)  were  generated. Cells 
were analyzed for surface expression of Kit by FACS analysis. Flow cytometric 
analysis revealed surface expression of these proteins (Figure 10). Western blot 
analyses showed two different forms of the Kit protein with different molecular 
weights: the heavily glycosylated (mature) form with a molecular weight of 145 kD 
and the hypoglycosylated (immature) form with a molecular weight of 130 kD (data 
not shown).  
 
                                                 
 
Figure 10.  Expression of Kit proteins. Flow cytometric analysis of Kit surface expression on a 
stably expressing 32D cell line. The green areas show staining with anti-Kit antibody. The red areas 
show the isotype control.  
 
4.1.2  Cbl mutants confer ligand-independent growth in association with Kit  
Next, it was examined whether Cbl mutants expression lead to increased proliferation 
by performing growth curves of stable 32D cell lines. Cells expressing either Cbl 
mutant in the presence of Kit-WT rapidly proliferated in the absence of exogenous 
SCF or IL-3 (Figure 11A). After 72  hours, Cbl-70Z  led to  more than fivefold 
proliferation in the presence of Kit WT, compared to a 3-fold increase observed in the 
cell lines both Cbl-R420Q and Kit WT (Figure 11A). In contrast, in the absence of Cbl Results 
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mutants, cells co-expressing Kit WT alone did not proliferate in the absence of 
cytokines. Cultures expressing one of the Cbl mutants with Kit-WT survived for 
extended time periods in the absence of any growth factors (Figure 11B). As reported 
earlier, 32D cells expressing Cbl-70Z have shown moderate growth advantage and 
cell survival compared to cells expressing Cbl-R420Q (Hamilton et al, 2001).  After 
72 hours, a less significant fraction of cells was alive in the case of cells expressing 
Cbl-R420Q or Kit WT (Figure 11B). 
 
 
 
Figure 11. Cbl mutants synergize with Kit to induce autonomous growth and in vitro colony 
formation. (A) The 32D cells stably overexpressing Kit-WT and/or indicated Cbl mutants were starved 
from IL-3, and cells were grown in the presence of 10% FCS. Cells were counted at the indicated time 
points by the trypan blue exclusion method, and the data are shown as fold change of the cell number 
compared with the start of the experiment. (B) The percentage of cells in the culture that was alive at 
the indicated time points. The data represent the average and standard deviation of 3 independent 
experiments. 
 
4.1.3  Enhanced 
3[H]-thymidine incorporation in the presence of Cbl mutants 
and Kit WT 
The effect of Cbl mutants on IL-3 independent and SCF-dependent proliferation was 
analysed  in 
3[H]-thymidine incorporation assays. As in proliferation assays, co-
expression of Cbl mutants with Kit WT induced a proliferative growth advantage in 
the absence of SCF and this growth was further enhanced after SCF-stimulation 
compared to cells expressing Kit WT (Figure 12). Cells expressing Cbl-70Z and Kit 
WT showed  more SCF-dependent and independent growth compared to cells 
expressing Cbl-R420Q and Kit WT. Cbl-R420Q alone did not show SCF dependent 
or independent growth. Kit WT cells proliferated only in the presence of SCF.     
                             Results 
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Figure 12.  Enhanced 
3[H]-thymidine incorporation in the presence of Cbl mutants and Kit WT. 
The 32D cells stably expressing Kit-WT and/or Cbl constructs were starved from IL-3 for 12 hours and 
then cultured in the presence or absence of SCF or IL-3. Proliferation was measured by 
3[H]-thymidine 
incorporation assays. Data are shown as percentage of thymidine incorporation relative to the 
thymidine incorporation of the respective cell line with IL-3 supplementation. The data represent the 
average and standard deviation of 3 independent experiments. 
 
4.1.4  Cbl mutants confer clonogenic growth in cooperation with Kit WT 
To further investigate the transforming potential of the two mutant Cbl proteins, we  
 
 
Figure 13. Cbl mutants lead to cytokine-independent colony growth. (A) The 32D cells stably 
overexpressing Kit-WT and/or indicated Cbl mutants were serum starved for 12 hours and then plated 
at a concentration of 1.000 cells per dish in the absence of any growth factors. Colonies were counted 
on day 6. The assays were plated as triplicates. The numbers given show the results of one of at least 
3 independent experiments per construct, which all gave similar results. (B) Photographs of the dishes 
were taken on day 6 and show morphologic differences in clonal growth.     
 
examined their ability to confer clonogenic growth to 32D cells (Figure 13). When 
expressed in 32D cells, Cbl-70Z induced the formation of very few, small colonies in Results 
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the absence of growth factors (Figure 13B). In contrast, expression of Cbl mutants 
together with Kit induced the growth of numerous large and dispersed colonies 
(Figure 13A).  
 
4.2  Cbl mutants induce a generalized mastocytosis and a myeloproliferative 
disease in a murine bone marrow transplantation model 
4.2.1  Cbl mutants induce hematologic disorder 
To investigate the transforming capability of different Cbl mutants in vivo,  murine 
ecotropic retrovirus (pMY) expressing Cbl-R420Q or Cbl-70Z or vector alone were 
generated. A bicistronic retroviral vector co-expressing the Cbl mutants together with 
the enhanced green fluorescent protein (EGFP) via an internal ribosomal entry site 
(IRES) was used (Kitamura et al, 2003b). Bone marrow was transduced with each 
retrovirus at a titer of 4×10
5  retroviral particles per milliliter, analyzed by flow 
cytometry for EGFP expression and the total cell number was determined. 150.000 
EGFP positive cells were injected into the tail vein of lethally irradiated (8 Gy [800 
rad]) female Balb/C recipient mice. Initial control experiments showed a similar level 
of expression between Cbl-R420Q and Cbl-70Z (data not shown). Almost all 
recipients of bone marrow cells transduced with Cbl
  mutants developed a lethal 
hematologic disorder with a mean
 latency of 341 days in the Cbl-R420Q group and 
395 days in the
 Cbl-70Z group (Figure 14). Eleven of 13 mice in the Cbl-R420Q
 group 
and eight of 11 mice in the Cbl-70Z group died (Figure 14).    
 
                               
Figure  14. Cbl mutants induce hematologic disorder.  (A)  Kaplan-Meier survival curve for 
recipients of bone marrow transduced with Cbl-70Z, Cbl-R420Q or empty vector (Control).  (B) 
Analysis of mice; BM, bone marrow; PB, peripheral blood. Results 
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4.2.2  Cbl-R420Q mutant induce myeloid leukemia 
Two animals in the Cbl-R420Q group succumbed to a “myeloid leukemia with 
maturation” matching all 5 criteria for nonlymphoid leukemia of the Bethesda 
proposals  (Kogan et al, 2002).  These 2 mice showed leukocytosis of up to 
140.000/μL (Figure 19B) with more than 20% blasts in the peripheral blood (Figure. 
19A) and up to 70% blast infiltration in the spleen (Figure 18). Splenomegaly (Figure 
15) developed with large differences in spleen weights and expansion of myeloid 
cells in liver and spleen were observed (Figure 18).  
 
 
Figure 15. Cbl mutants cause splenomegaly. (A) Splenomegaly in mice that received transplants of 
Cbl mutant transduced bone marrow cells; empty vector (Control). (B) Comparison of spleen weight 
from mice receiving bone marrow transduced with Cbl mutants. 
 
.  
 
 
Figure 16.  Immunophenotype of peripheral blood, bone marrow and spleen.  Comparison of 
immunophenotype of peripheral blood (PB), bone marrow (BM) and spleen cells from mice receiving 
bone marrow transduced with Cbl mutants representing lineage-specific antigens (Kit, CD-11b, Gr-1, 
B220, CD3). The data represent the average and the standard deviation. Results 
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Histology sections of spleen, liver and bone marrow and FACS analyses of spleen, 
bone marrow and peripheral blood showed extensive infiltration of blasts and mature 
myeloid cells (Figures 16-18 and 19A) 
 
4.2.3  Cbl mutants induce a generalized mastocytosis 
Importantly, all the animals in the Cbl-R420Q and Cbl-70Z group showed a diffuse 
organ infiltration (spleen, liver, bone marrow, lung, kidney, heart) of mast cells with a 
very variable range of mast cell infiltration (Figures 17-18 and 20). Six mice showed 
increased mast cell infiltration, reminiscent of mast cell sarcoma. These cells have 
clear mast cell morphology with  numerous granules in Giemsa staining and are 
highly positive in NACE (naphthol AS-D chloroacetate esterase) staining. The lesions 
have characteristic cytology with uniform, closely packed cells with round nuclei and 
clear, abundant cytoplasm with granules, which are characteristic features of mast 
cells (Figures 17-18 and 20-21) 
 
 
 
Figure 17. Cbl mutants induce a myeloid leukemia or mast cell sarcoma. Histopathology of the 
bone marrow (BM) from mice transplanted with Cbl mutant transduced bone marrow cells. Bone 
marrow sections were stained with hematoxylin and eosin [HE], Giemsa, naphthol AS-D chloroacetate 
esterase [NACE]). They are from a representative leukemic mouse (Cbl-R420Q) and a mouse with 
mast cell sarcoma (Cbl-70Z), which received bone marrow cells transduced with Cbl-R420Q or Cbl-
70Z, respectively. Normal organ architecture is visible in a control mouse.  
 
 Results 
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Figure 18. Histopathology of the liver and spleen from mice transplanted with Cbl mutant 
transduced bone marrow cells.  Spleen, liver sections stained with hematoxylin and eosin [HE], 
Giemsa, naphthol AS-D chloroacetate esterase [NACE]). They are from a representative leukemic 
mouse (Cbl-R420Q) and a mouse with mast cell sarcoma (Cbl-70Z), which received bone marrow 
cells transduced with Cbl-R420Q or Cbl-70Z, respectively. Normal organ architecture is visible in a 
control mouse. The leukemic mouse (Cbl-R420Q) reveals a massive infiltration of immature myeloid 
cells with its maximum in the spleen and consecutive destruction of the normal organ structure. There 
are also mast cells sporadically visible in between the immature cell infiltration (see arrow in the 
spleen pictures and Giemsa staining). In contrast mast cells in the mice with mast cell sarcoma have 
characteristic cytology with uniform, closely packed cells with round nuclei and clear, abundant 
cytoplasm with granules and the typical features of mast cells with numerous granules in Giemsa 
staining and are highly positive in NACE (naphthol AS-D chloroacetate esterase) staining. 
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Figure 19. Blood smear, white and red blood cell count, and immunophenotype of cells of 
peripheral blood of mice that received a transplant of Cbl mutant-transduced bone marrow. (A) 
Blood smear of peripheral blood with hyperleukocytosis in leukemic Cbl-R420Q mice (Pappenheim’s 
staining). (B–C) Leukemic Cbl-R420Q mice develop leukocytosis (B) and anemia (C). Peripheral blood 
leukocyte (WBC) and erythrocyte (RBC) counts for recipients of bone marrow transduced with Cbl 
mutants.  
 
One mouse had an organ infiltration of mast cells together with mature myeloid cells 
and 5-10% myeloid blast cells. Importantly, none of the control mice had histological 
evidence of mastocytosis or other hematological disease (Figure 17-18).  
 
4.2.4  Granules in mast cells  
Electron microscopic pictures reveal large cytoplasmic granules in the mast cells. 
These granules are round, oval or irregular bodies of 0.5 to 1.0 µm in size, having 
granules sharp boundaries which are sometimes wavy at points of contact with other 
granules and thus present the appearance of an interlocking of the surfaces of the 
granules. Inside the granules is found a reticular or vacuolar structure consisting of 
thread-like material which is similar to,  but finer than,  that of the interior of the 
nucleus (Figure 21). These features resemble granules of mast cells. 
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Figure 20. Histopathology of the heart from mice transplanted with Cbl mutant transduced 
bone marrow cells. Heart sections (hematoxylin and eosin HE, Giemsa, naphthol AS-D chloroacetate 
esterase NACE, original magnification 100–1000×) from a representative leukemic mouse (Cbl-
R420Q) and a mouse with mast cell sarcoma (Cbl-70Z), which received bone marrow cells transduced 
with Cbl-R420Q or Cbl-70Z, respectively. Normal organ architecture is visible in a control mouse 
(vector alone). A leukemic mouse (Cbl-R420Q) reveals a massive infiltration of immature myeloid cells 
in the heart. A mouse with generalized mastocytosis and mast cell sarcoma shows diffuse mast cell 
infiltration in between the heart muscle cells (see arrows). 
 
                
  Figure 21. Electron microscopy of mast cells (magnification see photo) 
 
Thus, bone marrow transplantation of cells expressing Cbl mutants
  led to a 
generalized mastocytosis (in extreme cases mast cell
 sarcoma), a myeloproliferative 
disorder and myeloid leukemia
 with a long latency and at high penetrance. 
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4.3  Cbl mutants inhibit ubiquitination of Kit  
The observation that Flt3 and Kit proteins cooperated with Cbl mutants to transform 
myeloid cells in vitro prompted us to study the underlying mechanisms. Under 
physiological conditions, ligand activation of RTKs induces receptor internalization 
and degradation that are important for RTK signal mitigation. Cbl proteins play an 
important role in these processes (Thien and Langdon, 2001;Waterman and Yarden, 
2001;Zeng et al, 2005). Therefore, we analyzed whether Cbl mutants can abolish 
ubiquitination of the activated Kit receptor. COS-7 cells were transiently transfected 
with Kit WT and HA-tagged ubiquitin (Ubq) in the presence or absence of Cbl 
mutants. 
   
                   
Figure 22. Cbl mutants inhibit ubiquitination of Kit. COS-7 cells were transiently transfected with 
the indicated constructs together with a plasmid for HA-tagged ubiquitin (Ubq). After 48 hours of 
transfection cells were serum-starved for 12 hours and stimulated with 50 ng/mL SCF for 10 minutes 
or left unstimulated. Cell lysates were prepared and equal amounts of lysates were 
immunoprecipitated using anti-Kit antibody. The immunoprecipitates were resolved on SDS-page and 
analyzed with anti-HA or anti-Kit antibodies. Expression of overexpressed Cbl mutants is shown in 
total cell lysates (TCL) using anti-Cbl antibody. 
 
After transfection, cells were stimulated with SCF. Kit was effectively ubiquitinated in 
the presence of endogenous Cbl WT after stimulation with SCF (Figure 22), but the 
presence of Cbl-R420Q completely abolished ubiquitination of the activated receptor. 
Cbl-70Z also repressed ubiquitination, although not to the same extent as in the case 
of Cbl-R420Q. In the control cells ubiquitination was not observed (Figure 22). The 
expression of Kit receptor and the Cbl mutants was similar in all cases.  Results 
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4.4  Cbl mutants inhibit internalization of ligand-activated Kit  
As ubiquitination often leads to endocytosis of the activated receptor (Ceresa and 
Schmid, 2000;Haglund et al, 2003;Le and Wrana, 2005), the effect of Cbl mutants on 
endocytosis of activated Kit receptor in 32D and  COS-7 cells  was examined. To 
avoid the end point differences in signal termination, between different cell types, 
COS-7 cells were used for both ubiquitination and endocytosis experiments. 
 
 
Figure 23.  Internalization of Kit is inhibited by Cbl mutants. 32D (A) or Cos-7 (B) cells expressing 
Kit in the presence or absence of different Cbl mutants were washed with PBS and then stimulated 
with SCF for the indicated time points. Subsequently the amount of Kit remained on the cell surface 
was measured by flow cytometry after staining with a PE-labelled anti-Kit antibody. Sodium azide was 
used to stop the internalization. Results are expressed as mean (+/-  standard deviation) of 3 
independent experiments. 
 
COS-7 cells transfected with Kit WT in the presence or absence of Cbl mutants or 
32D stable cell lines stimulated with SCF and the amount of Kit receptor at the 
surface was analyzed by FACS by using PE labeled Kit antibody, at the indicated 
time points. During first 10 mins of stimulation, approximately 15% of Kit protein was 
internalized, compared to 5% in the presence of Cbl mutants.  Cbl mutants quite 
effectively inhibited the initial rapid rate of ligand-induced receptor  internalization 
(Figure 23). 
 
4.5  Cbl mutants associate with Kit 
The physical interaction between the Cbl mutants and Kit was analysed.  32D cell 
lines stably expressing Kit WT in the presence of HA-tagged Cbl mutants were serum 
starved and stimulated with SCF.  
 Results 
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Figure 24.  Kit physically interacts with Cbl. 32D-Kit-WT cells stably transfected with HA-tagged 
Cbl proteins (Cbl-WT, Cbl-R420Q, Cbl-70Z) were deprived from cytokines overnight and subsequently 
exposed to the indicated cytokines for 10 minutes. Cbl proteins were immunoprecipitated by anti-HA 
antibodies and immunoprecipitates were resolved on SDS-PAGE. Co-immunoprecipitation of Kit was 
analyzed using anti-Kit antibodies. 
 
Immunoprecipitation of exogenously overexpressed, hemagglutinin (HA)–tagged c-
Cbl with anti-HA antibodies resulted in immunocomplexes that contained Kit (Figure 
24). The association of Cbl-WT and Cbl-R420Q with Kit was apparently enhanced by 
the presence of SCF, whereas Cbl-70Z strongly associated with Kit receptor in the 
presence of SCF and a slight association was present even in the absence of ligand 
(Figure 24). A slightly reduced level of Cbl expression was observed in the presence 
of Cbl-70Z. 
 
4.6  Akt and Erk activation in the presence of Cbl mutants and Kit WT 
The effects of Cbl mutants on receptor mediated downstream signaling pathways 
was analysed (Figure 25). 32D cells expressing Cbl mutants alone or in combination 
with Kit WT were serum starved and stimulated with either SCF or IL-3.  
Co-expression of Cbl-70Z or Cbl-R420Q with Kit receptors induced a stronger 
activation of the Akt and Erk pathways compared to cells expressing Kit WT alone as 
indicated by phosphorylation of the respective signaling intermediates after 10 
minutes (Figure 25B). Further, in the cells expressing Cbl mutants and Kit WT, Akt 
and Erk (to a lesser extent) were phosphorylated (i.e. activated) even in the absence 
of growth factors (Figure 25B). No activation of intracellular signaling mediators was 
observed when the Cbl mutants were overexpressed alone, except when cells were 
stimulated with IL-3 (Figure 25A). 
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Figure 25. Cbl influences Kit-mediated signaling. 32D cells with (B) and without Kit-WT (A) were 
engineered to express the indicated Cbl proteins, deprived from cytokines overnight and subsequently 
exposed to the indicated cytokines for 10 minutes. Western blot analyses with the indicated antibodies 
were performed. 
 
4.7  Cbl mutants prolonged Kit mediated signaling 
Next, the effects of Cbl proteins on the strength, quality, and duration of Kit signaling 
were analysed. 32D cells expressing Kit WT in the presence or absence of Cbl 
mutants were serum starved and then stimulated with SCF for 240 mins. In the cells 
expressing Kit alone, maximum stimulation of Kit receptor was observed after 10mins 
and the signal intensity was decreased thereafter. Nevertheless, cells expressing Kit 
and Cbl mutants showed maximum stimulation of Kit receptor after 10mins (higher 
than in the cells expressing Kit alone) followed by persistent activation of Kit.   A 
prolonged activation of Kit, Akt and Erk activity up to 240 minutes after SCF 
stimulation in the cells expressing Cbl-70Z or Cbl-R420Q compared to the cells 
expressing Kit WT was observed (Figure 26).. 
 
 
 
Figure 26. Cbl proteins change the kinetics of Kit-phosphorylation and Kit-induced Akt and Erk 
activity. 32D-Kit-WT cells stably transfected with the indicated Cbl proteins were serum starved and 
then exposed to SCF for the indicated time periods. Western blot analyses using phospho-specific 
antibodies for Kit (A), Akt (B) and Erk1/2 (C) were performed. 
 
In  addition, Cbl-70Z expression, but not Cbl-R420Q or Kit WT alone, led to 
autophosphorylation of the Kit receptor even in the absence of any ligand (Figure Results 
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26A). Kit receptor was maximally  stimulated in the presence of Cbl mutants 
compared to cells expressing Kit alone (Figure 26A). 
 
4.8  Kinase activity of Kit and Flt3 is dispensable for Cbl-70Z mediated 
transformation 
In order to determine the requirement of RTK kinase activity during the 
transformation by Cbl mutants and Kit receptor, 32D cells stably expressing kinase-
dead (KD) mutants of Kit (Kit-D790N, Kit-KD) in the presence or absence of Cbl 
mutants were generated.  
 
 
 
Figure 27. Kinase activity of Kit is dispensable for Cbl-70Z mediated transformation. (A) The 
32D cells stably overexpressing Kit-KD and/or indicated Cbl mutants were starved from IL-3 and cells 
were grown in the presence of 10% FCS. Cells were counted at the indicated time points by the trypan 
blue exclusion method and the data are shown as fold change of the cell number compared with the 
start of the experiment. (B) The percentage of cells in the culture that were alive at the indicated time 
points are shown. (C) 32D-Kit-KD cells stably overexpressing the indicated constructs were starved 
from IL-3 for 12 hours, treated with the indicated cytokines and proliferation was measured in 
3[H]-
thymidine incorporation assays.  
 
Analyzing the proliferative capacity of cells that co-express Kit-KD and Cbl-R420Q, it 
was  found a  surprising  growth and survival advantage when  compared to Kit-KD 
alone (Figure 27A-B). This effect was more pronounced with Cbl-70Z than with Cbl-
R420Q. Interestingly, cells co-expressing Kit-KD and Cbl-70Z rapidly proliferated and 
survived for extended time periods in the absence of exogenous growth factors 
(Figure 27).  Kinase-dead Flt3 (Flt3-K644A, Flt3-KD)  expressing 32D cells  in the 
presence and absence of Cbl mutants were generated. Cells co-expressing Flt3-KD 
and Cbl-70Z also proliferated and survived in the absence of growth factors (Figure 
28). 
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Figure 28. Kinase activity of Flt3 is dispensable for Cbl-70Z mediated transformation. (A) The 
32D cells stably overexpressing Flt3-KD and/or indicated Cbl mutants were starved from IL-3 and cells 
were grown in the presence of 10% FCS. Cells were counted at the indicated time points by the trypan 
blue exclusion method and the data are shown as fold change of the cell number compared with the 
start of the experiment. (B) The percentage of cells in the culture that were alive at the indicated time 
points are shown. (C) 32D Flt3-KD cells stably overexpressing the indicated constructs were starved 
from IL-3 for 12 hours, treated with the indicated cytokines and proliferation was measured in 
3[H]-
thymidine incorporation assays. Data are shown as percentage of thymidine incorporation relative to 
the thymidine incorporation of the respective cell line with IL-3 supplementation. The data (panel A) 
represent the average and standard deviation of at least 3 independent experiments. 
 
Viability assays (data not shown) and 
3[H]-thymidine incorporation assays confirm 
that  both kinase-dead receptors were not responsive to their respective ligands 
(Figure 27 and 28). 
 
4.9  Role of Akt in Cbl-70Z transformed Kit kinase dead cells 
To determine what signaling molecules supported the transforming effect of Cbl-70Z, 
Akt, Erk and Stat pathways were analysed in 32D cell lines co-expressing Kit-KD or 
Flt3-KD and Cbl-70Z or Cbl-R420Q. Surprisingly, it was found ligand independent 
activation of Akt in the cell lines expressing Cbl-70Z in the presence of either of the 
KD receptors, but not in the cells expressing Cbl-R420Q and kinase-dead receptors 
or control cells (Figure 29A-B).  No differences were found in other pathways 
(Stat/Erk) (Figure 29A). 
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Figure 29. Constitutive Akt activation in Kit-KD cells expressing Cbl-70Z. (A) 32D cells with Kit-
WT or Kit-KD were engineered to express the indicated Cbl proteins, deprived from cytokines 
overnight and subsequently exposed to the indicated cytokines for 10 minutes. Western blot analyses 
with the indicated antibodies were performed. (B) 32D cells overexpressing Kit-KD and Cbl-70Z were 
deprived from cytokines overnight and subsequently exposed to the indicated cytokines for 10 
minutes. Western blot analyses with the indicated antibodies were performed. (C) Kit-KD cells stably 
overexpressing Cbl-70Z were starved from IL-3 and cells were grown in the presence of 10% FCS and 
10 to 15 μM Akt inhibitor or DMSO as solvent. Cells were counted at the indicated time points by the 
trypan blue exclusion method and the data are shown as fold change of the cell number compared 
with the start of the experiment. 
 
4.9.1  Akt inhibition abolished transformation  
Importantly, inhibition of Akt activity  abolished the cytokine-independent growth  of 
these cells (Figure 29C).  Growth was inhibited in dose dependent manner. After 
72hrs, almost all cells were died in the presence of Akt inhibitor. Cells expressing 
Flt3-KD and Cbl-70Z also died in the presence of Akt inhibitor (data not shown). 
 
4.9.2  Cbl-70Z do not confer autophosphorylation to kinase-dead (KD) 
receptors  
The presence of Cbl-70Z conferred ligand-independent autophosphorylation to Kit 
WT (Figure 26A), whilst autophosphorylated kinase-dead receptors in the absence or 
presence of any dominant-negative Cbl mutant was undetectable (Figure 30). Results 
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Figure  30. Cbl mutants do not confer autophosphorylation to the Kinase-dead receptors.                                                                                                              
32D cells with Kit WT or Kit-KD were engineered to express the indicated Cbl proteins, deprived from 
cytokines overnight and subsequently exposed to the indicated cytokines for 10 minutes. Western blot 
analyses with the indicated antibodies was performed. 
 
4.9.3  Kinase-dead Kit receptor does not undergo ubiquitination 
In order to understand the basic mechanism of degradation of this receptor the 
turnover of the kinase-dead Kit receptor by ubiquitination experiments was analysed. 
No degree  of ubiquitination of the receptor, compared with the basic level of the 
unstimulated Kit WT receptor was observed (Figure 31).  
                              
                                      
Figure 31. Kit-KD is not ubiquitinated. COS-7 cells were transiently transfected with the indicated 
constructs together with a plasmid for HA-tagged ubiquitin. 48 hours post-transfection cells were 
serum-starved for 12 hours and stimulated with 50 ng/mL SCF for 10 minutes or left unstimulated. Cell 
lysates were prepared and equal amounts of lysates were immunoprecipitated using anti-Kit antibody. 
The immunoprecipitates were resolved on SDS-PAGE and analyzed with anti-HA or anti-Kit 
antibodies. 
 
Taken together, Cbl-70Z and Cbl-R420Q not only strongly synergized with 
unstimulated receptor tyrosine kinases with intact kinase function, but surprisingly 
also induce biologically meaningful signaling events emanating from kinase-inactive 
class III receptor tyrosine kinases. Results 
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4.10 Src family tyrosine kinases (SFKs) are necessary for Cbl-70Z-mediated 
transformation 
4.10.1 Enhanced SFKs activity in the presence of Cbl mutants  
SFKs play an important role in intracellular signaling processes, for example of 
cytokine receptors. These receptors do not have tyrosine kinase activity (Miyajima et 
al, 1993;Parsons and Parsons, 2004). Based on the observation of RTK independent 
proliferation in the cells expressing RTKs and Cbl mutants, it was speculated that 
whether SFKs could play a role in Cbl-70Z  mediated transformation. First, SFKs 
activation status in the presence of Cbl mutants was analysed. In 32D cells, it was 
observed that some SFKs were already constitutively active in the absence of any 
growth factors; this activation was not further enhanced by IL-3 stimulation but was 
strongly enhanced in the presence of both Cbl mutants (data not shown). In addition, 
the  overexpression of Kit in the presence of Cbl mutants showed a similar 
phosphorylation of SFKs irrespective of the kinase activity of the RTK (Figure 32). 
 
                      
 
Figure 32. Phosphorylation of SFKs is enhanced by Cbl mutants. The 32D-Kit-WT (top 2 blots) or 
32D-Kit-KD (bottom 2 blots) cells stably overexpressing the indicated Cbl proteins were starved from 
IL-3 overnight and subsequently exposed to the indicated cytokines for 10 minutes. Western blot 
analyses using the phosphospecific antibody recognizing the activated form of SFK members (anti-
pSrc Y416) and anti–β-actin antibody were performed as described. 
 
4.10.2 Constitutive association of Kit-KD, Cbl and SFKs 
The binding of Kit-KD, Cbl proteins and SFKs was examined. Immunoprecipitation 
experiments showed a constitutive association between SFKs and Cbl proteins in the 
absence of Kit (Figure 33).  Surprisingly, immunoprecipitation of Cbl mutants also 
resulted in immunocomplexes with Kit-KD (Figure 33). Differences in the expression Results 
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levels of Cbl mutants can be excluded as reason for the different phenotypical 
behavior of these mutants (Figure 33 and data not shown). The association of Cbl 
mutants with Kit-KD was not enhanced by the presence of SCF.  
 
 
 
Figure 33. Cbl mutants physically interact with the KD Kit receptor. The 32D cells with or without 
Kit-KD stably transfected with HA-tagged Cbl proteins (Cbl-R420Q and Cbl-70Z) were starved from IL-
3 overnight and subsequently exposed to the indicated cytokines for 10 minutes. Cbl proteins were 
immunoprecipitated by anti-HA antibodies, and immunoprecipitates were resolved on SDS-PAGE. 
Coimmunoprecipitation of Kit and p-SFKs was analyzed using anti-Kit or anti–phospho-SFK 
antibodies. 
 
4.10.3 SFK inhibitors inhibit SFK phosphorylation 
Cbl mutants associated with the kinase-dead Kit receptor which could be a 
prerequisite for the transformation potential of Kit-KD together with Cbl mutants. To 
test this hypothesis, the well established Src family inhibitors PP-1, PP-2  and 
dasatinib  (Choudhary et al, 2007;Ramirez and DiPersio, 2008)  were used.  In  the 
presence of Src inhibitors,  the phosphorylation of SFKs was completely inhibited 
(Figure 34). 
 
                         
 Results 
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Figure 34. SFK phosphorylation is inhibited by Src inhibitors PP-1, PP-2, and dasatinib. 32D 
cells stably expressing the indicated constructs were starved in 10% FCS in the presence of PP-1, PP-
2, Dasatinib or DMSO as control. Cell lysates were prepared as described, resolved on SDS-PAGE, 
and membranes were blotted for phospho-SFK and β-Actin. 
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4.10.4 Role of Fyn 
Furthermore, PP-2 completely abrogated the interaction between activated SFKs and 
Cbl (Figure 35A), indicating a central role of activated SFKs. In order to identify the 
SFK  involved in this process,  Cbl  was  immunoprecipitated  and blotted for each 
individual Src family members. These experiments revealed that Fyn, a SFK, binds to 
Cbl in a phospho-dependent manner, but not Lck, Hck, Src, Yes, and Lyn (Figure 
35B, and data not shown). 
 
 
Figure 35. Interaction of SFKs and Cbl proteins is completely inhibited by the Src inhibitor PP-
2. (A) The 32D-Kit-KD cells stably overexpressing HA-tagged Cbl-70Z were starved from IL-3 in the 
presence of DMSO or PP-2 (15 µM) for 12 hours. Cbl proteins were immunoprecipitated by anti-HA, 
antibodies and immunoprecipitates were resolved on SDS-PAGE. Western blot analyses were 
performed with anti–phospho-SFK and anti-HA antibodies. (B) The 32D-Kit-KD cells stably 
overexpressing HA-tagged Cbl-70Z were starved from IL-3 in the presence of DMSO or PP-2 (15 µM) 
for 12 hours. Cbl proteins were immunoprecipitated by anti-HA antibodies and immunoprecipitates 
were resolved on SDS-PAGE. Coimmunoprecipitation of Fyn was analyzed using anti-Fyn antibody. 
 
4.10.5 SFKs inhibition abolished Cbl-70Z transformation 
Proliferation assays of cells co-expressing Kit-KD or Flt3-KD together with Cbl-70Z 
were unable to grow in the presence of PP-1 or PP-2 (Figure 36A). Finally, the effect 
of the Src inhibitors on the clonogenic growth mediated by Cbl mutants  was 
investigated. Importantly, the presence of Src inhibitor PP-2 significantly inhibited the 
clonogenic growth in the presence of Cbl mutants and Kit or Flt3 receptor (Figure 
36B). Results 
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Figure 36. Cbl-70Z–mediated ligand-independent DNA synthesis is blocked by Src inhibitors. 
(A) 32D cells stably expressing Kit, Flt3 and/or Cbl-70Z were starved from IL-3 for 12 hours, treated 
with the indicated cytokines and PP-1/PP-2 (15 µM) or DMSO for 6 hours, and incubated with 
3[H]-
thymidine. After 15 hours of incubation, proliferation was measured in 
3[H]-thymidine incorporation 
assays. Data are shown as percentage of thymidine incorporation relative to the thymidine 
incorporation of the respective cell line with IL-3 supplementation. The data represent the average and 
SD of 3 independent experiments. (B) The 32D cells stably overexpressing Kit or Flt3 constructs 
and/or Cbl-70Z were serum starved for 12 hours and then plated at a concentration of 1000 cells per 
dish in the presence or absence of PP-2 (15 µM) and in the absence of any growth factors. Colonies 
were counted on day 6. The assays were plated as triplicates. The numbers given show the results of 
1 of at least 3 independent experiments per construct, which all gave similar results. 
 
4.10.6 Src inhibitors inhibit Akt pathway 
After  determining a  prominent role of Fyn, we hypothesized that Fyn  might be 
activating the PI-3-Kinase/Akt pathway either directly or by phosphorylating Cbl at 
tyrosine 731, since tyrosine 731 is a PI-3-Kinase binding site. Surprisingly, dasatinib 
and PP-2 completely inhibited Akt activation and Cbl phosphorylation at 731 (Figure 
37).   
 Results 
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Figure 37. Src inhibitors inhibit phosphorylation of Akt.  (A)  The 32D-Kit-KD cells stably 
overexpressing HA-tagged Cbl-70Z were starved from IL-3 in the presence of DMSO or PP-2 (15 µM) 
or dasatinib (150 nM) for 12 hours. Western blot analyses were performed with anti–phospho-Akt and 
anti-Akt antibodies. (B), 32D cells stably expressing the indicated constructs were starved in 10% FCS 
in the presence of PP-1 (only panel B), PP-2, Dasatinib or DMSO as control. Cell lysates were 
prepared as described, resolved on SDS-PAGE, and membranes were blotted for phospho-SFK and 
β-Actin (panel B) or for pan phospho-Cbl, phospho-Y731-Cbl, and total Cbl.  
 
4.10.7 Kinase activity is required, but not essential  
 
                                         
 
Figure 38. Imatinib and dasatinib  differently  inhibit cell proliferation.  32D cells stably 
overexpressing Kit WT or Kit-KD along with Cbl-70Z were starved from IL-3, and cells were grown in 
the presence of 10% FCS or along with Kit inhibitor imatinib (2.5 µM) or dual kinase inhibitor (Kit and 
SFKs) dasatinib (150 nM). Cells were counted at the indicated time points by trypan blue exclusion 
method, and the data are shown as fold change of the cell number compared with the start of the 
experiment. The data represent the average and SD of 3 independent experiments. 
 
Furthermore, imatinib (as inhibitor of Kit) and dasatinib (as an inhibitor of both Kit and 
SFKs) was used (Ramirez and DiPersio, 2008) to demonstrate that the growth and Results 
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survival mediated by Cbl mutants is SFK dependent. As shown in Figure 38, 
dasatinib strongly inhibited the proliferation of Kit-WT (or Kit-KD) cells overexpressing 
Cbl-70Z, whereas imatinib reduced proliferation to a much lesser extent, most 
probably because imatinib does not inhibit SFKs (Figure 38). 
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5  Discussion  
Receptor tyrosine kinases (RTKs) play a pivotal role in embryonic development and 
in hematopoiesis. Extracellular binding of a ligand to its respective RTK induces 
dimerization followed by intracellular signaling (Schlessinger, 1988). The amplitude 
and duration of RTK signaling is tightly controlled; termination of RTK signaling 
occurs by receptor ubiquitination, internalization  and degradation (Ceresa and 
Schmid, 2000;Haglund et al, 2005;Le and Wrana, 2005). Aberrant activation of RTKs 
can be induced by inappropriate ligand stimulation or by overexpression due to 
genetic amplification or by activating or sensitizing mutations in the coding region of 
the RTKs (Basson et al, 2005;Peschard et al, 2001b;Peschard and Park, 2003;Zheng 
et al, 2004). In addition, inappropriate activation of RTKs by loss of negative 
regulators is increasingly recognized as a possible alternative mechanism to lead to 
aberrant RTK activity in cancer cells (Basson et al, 2005;Peschard et al, 
2001b;Peschard and Park, 2003;Zheng et al, 2004). The RTKs Flt3 and Kit play an 
important role in leukemogenesis (Blume-Jensen and Hunter, 2001b;Brandts et al, 
2007b;Stirewalt and Radich, 2003). Approximately 25% of all AML patients carry 
mutations in Flt3, whereas Kit mutations are found less frequently. Kit mutations have 
been preferentially associated with the core-binding factor leukemias (Beghini et al, 
2000b). Activating mutations of Flt3 (such as Flt3-ITD and activating point mutations 
in the tyrosine kinase domain, Flt3-TKD) lead to aberrant signal transduction. ITD 
mutations lead to constitutive receptor dimerization and activation of receptor as well 
as the activation of the STAT5, RAS/MAPK and PI3K pathway. These mutations 
have spurred considerable interest in the development of specific tyrosine kinase 
inhibitors for these RTKs (Beghini et al, 2000a;Brandts et al, 2007b;Paschka et al, 
2006b).  
 
Cbl mutants confer factor-independent growth in association with Kit 
Our group was the first
 to report a Cbl oncogenic mutation in a single case of 150 de 
novo AML patients (Sargin et al, 2007). The identified point mutation Cbl-R420Q has 
also been found by others (Grand et al, 2009;Sanada et al, 2009).  Our group have 
previously analyzed the role
 of this Cbl mutant in Flt3 signaling (Sargin et al, 2007). 
The Cbl mutant Cbl-70Z was identified in a mouse B-cell lymphoma. Cbl-R420Q and 
Cbl-70Z
  were able to confer IL-3-independent growth
  to the 32D cell line in the 
presence of wild-type Flt3 receptor  (Sargin et al, 2007). Several more additional Discussion 
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mutations were subsequently found in Cbl and Cbl-b (Abbas et al, 2008;Dunbar et al, 
2008;Grand et al, 2009;Loh et al, 2009;Makishima et al, 2009;Sanada et al, 
2009;Sargin et al, 2007) suggesting that Cbl mutations are recurring events in AML. 
Cbl mutations probably occur in other hematologic and solid tumors as well.  
Cbl has been shown to degrade several RTKs, including the EGFR and PDGFR 
(Schmidt and Dikic, 2005;Thien and Langdon, 2001;Thien and Langdon, 
2005a;Thien and Langdon, 2005b). Recently, it was showed that Flt3 is degraded in 
a Cbl-dependent manner (Sargin et al, 2007). Hematopoietic stem cells (HSC) and its 
progenitor cells express Kit. In this study, it was studied, if Cbl mutants alter the Kit 
signaling. To address this question, a myeloid cell line 32D was used, to study the 
signaling events of Kit in the presence or absence of Cbl mutants.  32D cells are an 
immortalized myeloblast like cell line originally derived from long-term cultures of 
murine bone marrow supplemented with WEHI-3B conditioned medium as an IL-3 
source. Removal of IL-3 arrests 32D cells in the G0/G1 phase of the cell cycle and 
prolonged removal leads to cell death. As shown here, the expression of Kit in 
myeloid 32D cells does not lead to cytokine-independent growth. In the present 
study, over-expression of Cbl mutants in the 32D cell line does not lead to factor-
independent growth. As previously reported, Cbl-70Z expression (alone) enhanced 
cell survival, but does not lead to factor-independent growth (Hamilton et al, 2001). It 
has been reported that dominant-negative Cbl mutants enhance the survival of 
myeloid cells (Hamilton et al, 2001). However, as in this report, they alone did not 
support cellular proliferation (Hamilton et al, 2001).  However, in the presence of Kit, 
Cbl-R420Q or Cbl-70Z expression promotes cytokine-independent growth. This effect 
can be enhanced after SCF stimulation. Similarly, coexpression of Kit with either Cbl-
R420Q or Cbl-70Z promotes survival and proliferation. In addition to trypan blue 
assays, thymidine incorporation assays also show that Cbl mutants synergize with Kit 
in order to give factor-independent to the myeloid cell line. Our results indicate that 
Cbl-70Z is stronger than Cbl-R420Q towards the transformation of myeloid cell line. 
We observed similar effects with Flt3, (Sargin et al, 2007) suggesting that this may be 
a general mechanism in most RTKs. It is of future interest to determine these types of 
synergistic events in other cancer types. 
Colony formation assays, which involve growing of cells in a semi solid media, are 
generally used to study  the transformation property of cells. As  shown here,  co-
expression of Kit and either of the Cbl mutants leds to colony growth in the absence Discussion 
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of growth factors. Cbl-70Z expression alone, but not Cbl-R420Q  formed few and 
small colonies. This indicates that Kit and Cbl mutant expression are essential for 
complete transformation. The  data  presented here  provides  evidence that Cbl-
mediated regulation of Kit is biologically important. In summary, coexpression of Cbl-
70Z or Cbl-R420Q with Kit readily transformed 32D cells, even in the absence of Kit 
ligand. Many of the AML cases overexpress Kit or Flt3 without harboring any 
mutations (Blume-Jensen and Hunter, 2001b). Our results may explain the possibility 
of these types of synergistic events in AML patients expressing Flt3 WT and Kit WT.  
 
Cbl mutations are rare, but recurring events in hematological disease 
Recently, missense mutations in exon 8 were reported in three out 12 AML cases 
(Caligiuri et al, 2007a). Other studies have also shown Cbl exon 8 splice variant 
mutations; these mutations were associated with CBF leukemias (Abbas et al, 
2008;Reindl et al, 2009). In addition, several reports have shown somatic Cbl 
mutations in the critical linker and ring finger domains (exons 8 and 9) (Makishima et 
al, 2009;Sanada et al, 2009). These are frequent in myeloid malignancies, 
particularly (but not exclusively) in myelodysplasia/myeloproliferative neoplasms 
(MDS/MPN) with acquired uniparental disomy (aUPD) at chromosome 11q (Dunbar 
et al, 2008;Grand et al, 2009;Loh et al, 2009). It is not yet clear how frequently Cbl 
mutations occur in AML, but probably less than 2% of cases.  No Cbl mutations were 
observed in mature lymphoid malignancies.  
 
Cbl mutants induce a generalized  mastocytosis and a myeloproliferative 
disease in a murine bone marrow transplantation model 
So far, the role of Cbl mutations in mouse models had not been determined. In in vivo 
study, the role of Cbl mutants in a bone marrow  transplantation  model  was 
addressed.  Two  distinct diseases  such as a generalized mastocytosis and a 
myeloproliferative disease with high penetrance and long latency were observed. In 
addition, two mice developed a myeloid leukemia with high leukocyte counts, 
splenomegaly, and organ infiltration by myeloid immature cells. Six mice developed 
mast cell sarcomas. Mastocytosis is defined as heterogeneous disorder, 
characterized by the expansion and accumulation of mature mast cells (MC) in a 
different organs and tissues, such as skin, gastrointestinal tract, liver, spleen, bone Discussion 
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marrow and lymphoid organs (Edling and Hallberg, 2007;Kitamura and Hirotab, 
2004;Lennartsson et al, 2005). 
Mast cells were identified in spleen, liver, bone marrow,
 lung, kidney, heart, indicating 
that it is generalized mastocytosis. Activating mutations of Kit have been identified in 
mastocytosis patients. Mostly, these mutations (D816V, D816Y and D820G) were 
found in the kinase domain of Kit (Orfao et al, 2007). Some JMD mutations (at 
codons 509, 522 and 533) were also found in mastocytosis patients. Kit mutation 
D816V has been first reported in the mastocytosis cell line HMC-1 (Furitsu et al, 
1993). A tantalizing explanation for the increased mast cell proliferation could be the 
typical expression of Kit in these cells. Future studies are warranted to test if Cbl 
mutations occur in mastocytosis patients with or without  Kit mutations. It is also 
possible, that Cbl mutations synergize with Kit mutations more strongly when 
compared to normal Kit WT.  
Mast cell activation  plays a significant role in allergy. IgE receptor aggregation on 
mast cells releases  inflammatory mediators by degranulation leading to the 
production of the multiple cytokines and leukotrienes which cause allergic symptoms. 
Furthermore, upon activation of the IgE receptor the SFK Lyn is activated, which in 
turn  phosphorylates  the IgE receptor (Kyo et al, 2003).  Over-expression of Cbl 
(membrane-anchored form of Cbl) inhibits the IgE-receptor-mediated degranulation 
and cytokine production by the degradation of Lyn through enhanced ubiquitination 
(Kyo et al, 2003). Here, Cbl mutants might have interfered WT Cbl function and finally 
led to the mastocytosis. An inhibitor of the mast cell activation might have therapeutic 
potential. Cbl may be the candidate molecule for developing novel anti-allergic drugs. 
In conclusion, our results indicate that Cbl mutations
  might contribute to the 
pathogenesis of mastocytosis and related diseases. 
The long latency observed in mouse model is very suggestive of secondary events, 
such  mutations  and  epigenetic changes.  Different  secondary events may  have 
occured  in different animals, at different times with different rates, explaining the 
variability of disease onset and death. Further evidence for  the requirement of 
cooperating genetic (or epigenetic) events comes from published mouse studies in 
which either complete Cbl knockout or heterozygous knock in of the RING finger 
inactivating mutant C379A (mouse C379 is equivalent to human C381) did not show 
any evidence of an MPN or other malignancy (Thien et al, 2005).  Here, postmortem 
analysis of Cbl expression was not performed, as endogenous Cbl is widely Discussion 
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expressed. As the Cbl mutants affect the stability of several intracellular and surface 
molecules, including Flt3 and Kit in these in vivo experiments, we were unable to 
pinpoint the contribution of the Cbl targets to the disease phenotype. Although 
unproven, the similarity of Cbl-70Z and Cbl-R420Q in disease development suggests 
a similar mechanism for both mutants. A recent report showed that hematopoietic 
stem cells from Cbl
-/- mice have an increased pool size, are hyperproliferative, and 
show enhanced long-term repopulating capacity (Rathinam et al, 2008). It is tempting 
to speculate that Cbl-inactivating mutations may promote similar function in leukemia-
initiating cells. Importantly, Cbl
-/-  hematopoietic stem cells expanded more in the 
presence of SCF and thrombopoietin, which is explained by the fact that Cbl is the 
negative regulator of Kit and the thrombopoietin receptor (cMpl) and supports the 
validity of increased SCF responsiveness we observed in cells coexpressing Kit and 
Cbl mutants. NUP98-HOXD13 (NHD13) fusion gene plays an important role in 
myelodysplastic syndrome and acute nonlymphocytic leukemia. Recently, an 
acquired Cbl mutation was shown in a Nup98-HoxD13 mouse model, which strongly 
supports the prominent role of Cbl mutations in vivo (Slape et al, 2008). Another 
report  (Sanada et al, 2009)  shows that Cbl can act as tumorsuppressor. In that 
report, Cbl
-/- hematopoietic stem/progenitor cells (HSPCs) show enhanced sensitivity 
towards different kinds of cytokines, compared to Cbl
+/+  HSPCs, and further 
transduction of gain-of-function  Cbl  mutants into Cbl
-/-  HSPCs augmented their 
sensitivities to a broader spectrum of cytokines, including SCF, TPO, IL3 and FL, 
indicating that function-gain-mutations in Cbl perform drastically in the absence of Cbl 
WT. Acquired uniparental disomy (aUPD) is frequently observed in cancer genomes 
and leads to loss of heterozygosity. aUPD is associated with loss-of-function 
mutations of tumor suppressor genes (Knudson, 2001) and also with gain-of-function 
mutations of proto-oncogenes (James et al, 2005). aUPD, which is more common in 
myeloproliferative neoplasms (MPN), generally associated with the following 
chromosomes, 1p, 1q, 4q, 7q, 11p, 11q, 14q, 17p and 21q. Cbl mutations were 
identified in most of the 11q aUPD cases (MPN) (Sanada et al, 2009). Out of these 
Cbl mutations, most of them were found to be homozygous, indicating the loss of Cbl 
WT and gain-of-function of the Cbl mutants. Furthermore our experiments, including 
bone marrow transplantation experiments, were carried out in the presence of 
endogenous Cbl WT. Cbl mutants (Cbl-R420Q and Cbl-70Z), would have shown 
more drastic effects (reduced latency), if  the experiments were carried out in the Discussion 
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absence of Cbl WT. Therefore, it is interesting to conduct the experiments in the 
absence of endogenous Cbl. 
The  in vivo  data presented in  this report is  the  first evidence that a Cbl mutant, 
identified from human malignancy, is involved in disease pathogenesis. The minor 
differences observed between Cbl-R420Q and Cbl-70Z are within the variability of 
animal experimentation.  
 
Cbl mutants abolished the ubiquitination and endocytosis of the Kit receptor 
It is well established that an intact RING domain is required for the E3 ligase activity 
of Cbl (Swaminathan and Tsygankov, 2006;Waterman et al, 1999). Several ubiquitin 
ligases, including Nedd4, have been involved in the ubiquitination of RTKs in 
mammalian cells (Dikic and Giordano, 2003). However, it is generally believed that 
the Cbl family ubiquitin ligases play most prominent role in mediating ligand activated 
RTKs. RTKs, such as EGFR, ErbB2, PDGF, colony-stimulating factor 1 receptor and 
hepatocyte growth factor receptor undergo ubiquitination upon interaction with Cbl 
(Dikic and Giordano, 2003). Generally, Cbl binds to RTKs (EGFR) at the plasma 
membrane and is  continuously associated in a complex throughout the endocytic 
route. Furthermore,  Cbl is also recruited from the cytoplasmic pool into the 
endosome, for the continuous ubiquitination and subsequent degradation of RTKs in 
the lysosomes.  
Cbl-70Z and Cbl-R420Q have a disrupted RING domain and are E3 ligase defective 
(Sargin et al, 2007). In our observations, Cbl-R420Q and Cbl-70Z prevented 
ubiquitination and endocytosis of Kit. Cbl-R420Q has suppressed the ubiquitination 
more effectively than Cbl-70Z. Termination of RTK signaling is a complex multistep 
process, which requires several sorting, segregation, and degradation steps, each of 
which involve many different proteins (Marmor and Yarden, 2004;Mousavi et al, 
2004;Seto et al, 2002). It may well be that other proteins involved in these processes 
may be mutated more frequently in AML and possibly in other human cancers. This 
notion, at least in part, is also supported by data showing that proteins involved in the 
endocytosis machinery are often constituents of oncogenic fusion proteins (Crosetto 
et al, 2005;Magnusson et al, 2001). Furthermore, inappropriate expression of 
proteins involved in endocytic sorting (i.e., Hrs and Tsg101) has also been implicated 
in human cancers. The potent effects of the point mutation of Cbl on myeloid cell 
proliferation and survival warrant further search for such mutations in clonal myeloid Discussion 
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disorders, especially in patients without known activating mutations in signaling 
intermediates.  
 
Cbl mutants constitutively activate Akt and MAPK pathways 
Originally, Cbl was described as a proto-oncogene of an animal virus that induced 
lymphoma in mice (Langdon et al, 1989c). It has been shown that the corresponding 
viral oncogene, v-Cbl, is a relatively weak oncogene (Thien and Langdon, 2001). v-
Cbl is a truncated protein, consisting of the N-terminal half of Cbl, retaining not much 
more than the PTB domain of Cbl. Subsequently, the description of other, more 
potent Cbl oncogenes led to the definition of requirements for the transforming 
potential of Cbl proteins (Peschard et al, 2001a;Thien and Langdon, 2001). Presence 
of the PTB domain and simultaneous interference with the E3 ligase function of Cbl 
has been defined to be essential minimal requirements for Cbl-mediated 
transformation. Most of these mutants are thought to act in a dominant-negative
 
manner by competing with the wild-type receptor. Our biochemical analyses here 
show that Cbl mutants fulfill these requirements. We were interested to further clarify 
the mechanisms of transformation by Cbl mutants and performed a careful analysis 
of the signaling properties conferred by Kit in the presence or absence of Cbl 
mutants. These experiments revealed enhanced basal RTK autophosphorylation and 
prolonged ligand-activated MAPK and PI3K/Akt signaling in the cells expressing Cbl 
mutants and Kit, which is in line with published data for EGFR (Thien and Langdon, 
1997) PDGFR (Bonita et al, 1997b) and Flt3 (Sargin et al, 2007). However, we also 
observed basal activation of Akt and Erk, which contrasts with data for Flt3, where no 
differences in Akt basal signaling were identified (Sargin et al, 2007). The reasons for 
this difference are unknown but may be the result of differences in Kit and Flt3 
expression. In any case, as Akt activation has been shown to cause cytokine-
independent colony growth (Brandts et al, 2005), this may partly explain why 
coexpression of Cbl mutants with Kit (in the absence of ligand) led to colony growth.  
 
Cbl-70Z associates with Kit constitutively 
Several reports have shown that Cbl and RTKs can interact either directly or 
indirectly through adaptor proteins such as Grb2, APS or the p85 subunit of PI3K. Cbl
 
binds to Kit directly and indirectly via Grb2 (Masson et al, 2006).  Cbl has been 
shown to interact with Kit in a direct manner at position Tyr
568 and Tyr
936, and that this Discussion 
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interaction is dependent on a leucine or isoleucine residue in position +3. Cbl is 
known
  to be phosphorylated by Src family kinases (SFKs) and mediates
 
ubiquitination
 of the Kit receptor on activation (Masson et al, 2006). In this study, the 
binding of Cbl mutants to the Kit protein  was addressed.  Here, our 
coimmunoprecipitation experiments showed that Cbl mutants are part of a complex 
with Kit after ligand stimulation. Importantly, Cbl-70Z (and to a lesser extent Cbl-
R420Q) coimmunoprecipitated with Kit in the absence of ligand. This suggests a 
constitutive complex formation between Cbl mutants and Kit, which was similarly 
observed for EGFR and Flt3 (Sargin et al, 2007;Thien and Langdon, 1997).  
AML blasts express Kit significantly higher compared with normal bone marrow 
(Scolnik et al, 2002)  and about one-third of AML blasts co-express Kit and SCF 
(Pietsch, 1993)  indicating paracrine  and autocrine growth mechanisms of human 
stem cell factor in myeloid leukemia. Here, Cbl mutants have enhanced SCF 
dependent growth and signaling. It is tempting to speculate that AML patients 
harboring Kit expression and Cbl mutations might have worse prognosis.  
The data reveal functional differences between Cbl-70Z and Cbl-R420Q. The loss of 
E3 ligase activity is more pronounced in cells expressing Cbl-R420Q than in those 
expressing Cbl-70Z, whereas the consequences of expression of either Cbl mutant 
appear to be very similar in both the in vitro and in vivo experiments with primary 
murine bone marrow. However, the biologic consequences of Cbl-70Z are more 
dramatic in cell culture experiments performed in 32D cells. Further studies are 
necessary to decipher these differences between Cbl mutants, including the novel 
mutations that have been described since our initial observation and have not yet 
been molecularly characterized (Abbas et al, 2008;Caligiuri et al, 2007b;Dunbar et al, 
2008;Grand et al, 2009;Makishima et al, 2009;Reindl et al, 2009;Sanada et al, 2009). 
However, it is possible that conformational changes or differences in sub cellular 
localization are involved.  
 
Kinase activity of Kit is not required for Cbl-70Z mediated transformation 
It was of interest,  in defining the kinase requirements of the Cbl mutants/RTK 
interaction. Importantly, the data revealed that the biologic functions mediated by Kit 
and Cbl-70Z were in large part dependent on the receptor kinase activity. Biologically 
dominant effect also observed in the presence of kinase-inactive Kit and Flt3 cells 
expressing Cbl mutants. Although it was not sufficient for cytokine-independent Discussion 
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growth that the cells expressed Cbl-70Z, KD Kit, and Flt3  synergized with Cbl 
mutants. It could be speculated that Kit or Flt3, which can be found to be in complex 
with the Cbl proteins, may act as a necessary scaffold. This is in line with a recent 
report that survival of cancer cells was maintained by EGFR independently of its 
kinase activity (Weihua et al, 2008). The yet unimpressive clinical outcomes of 
tyrosine kinase inhibitors for treatment of AML may be indicative  that kinase-
independent functions of RTKs may contribute to transformation.  
The potential signaling molecules that were assumed to be responsible for the Cbl-
70Z mediated transformation in the presence of Kit-KD were anlysed. Cbl-70Z has 
conferred autophosphorylation to the Kit WT receptor in the absence of SCF, in 
contrast to Ki-KD.  
 
Akt activation mediates the Cbl-70Z transformation 
It seems that kinase activity of the Kit is required, in order to undergo ubiquitination, 
since Kit-KD was not ubiquitinated in response to SCF. Finally, it was noticed that   
Akt activation is the driving force, for the proliferation of Kit kinase dead cells in the 
presence of Cbl-70Z. Generally, growth factor receptors upon activation activate PI-
3-kinase, which leads to accumulation of phosphatidylinositol
 trisphosphate at the cell 
membrane and binding of
 the serine-threonine kinase Akt via its pleckstrin homology
 
domain. At the cell membrane, Akt undergoes a conformational
  change and is 
phosphorylated on Thr
308 by PDK1 and Ser
478 by
 an unknown kinase, leading to Akt 
activation (Vivanco and Sawyers, 2002). Akt activation has been
 shown to mediate 
survival and proliferation (Vivanco and Sawyers, 2002).  Here, it was showed that Akt 
inhibition by its inhibitor abolishes transformation mediated by Cbl-70Z and Kit-KD. In 
addition, SFK’s inhibitors (PP-2 and dasatinib), inhibited the Akt activation. It 
indicates that SFKs are acting upstream to PI-3-Kinase/ Akt pathway as previously 
reported (Karnitz et al, 1994;Pleiman et al, 1994). Our data also shows that SFKs can 
activate Cbl by phosphorylating the tyrosine residue at 731, which is a PI-3-kinase 
binding site. In summary, SFKs can activate Akt either directly or by phosphorylating 
Cbl at tyrosine 731  (Thien and Langdon, 2001;Hunter et al, 1999b). Complete 
inhibition of proliferation and colonogenic growth of the cells expressing kinase dead 
receptors and Cbl-70Z has occurred in the presence of SFKs inhibitors (PP-1, PP-2 
and dasatinib). 
 Discussion 
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Role of Src family kinases (SFKs) in Cbl-70Z mediated transformation 
Cbl has been shown to degrade SFKs by ubiquitination (Kyo et al, 2003;Yokouchi et 
al, 2001). Increased SFK activity in the presence of Cbl mutants may be explained by 
lack of their degradation. This needs to be addressed in the future. In addition, we 
found, that Cbl-R420Q and Cbl-70Z in complex with Kit-KD and SFKs. Here Kit-KD 
might be playing scaffold role in assembling other potential molecules, besides to 
SFKs and Cbl-70Z. Previously, Fyn has been shown to bind (Hunter et al, 1999b) 
and phosphorylate Cbl, which leads to the activation of PI-3-Kinase. Our data shows 
that Fyn can bind Cbl.  However, its role is yet to be confirmed in the phosphorylation 
of Cbl.  
Kit inhibition by imatinib reduced the proliferation of cells over expressing Kit WT and 
Cbl-70Z stronger compared with cells expressing Kit-KD and Cbl-70Z, but much 
lesser than dasatinib, which inhibits both Kit and SFKs. This indicates that Kit kinase 
activity is required but not essential. These findings are extending and 
complementing our previous findings (Sargin et al, 2007). SFKs therefore are crucial 
components of the complex formed by kinase dead RTKs and Cbl mutants, and their 
inhibition prevents transformation. Generally, it is believed that the kinase activity of 
BCR-ABL is responsible for activation of all its downstream signaling pathways. 
Therefore,  BCR-ABL kinase activity inhibitors should completely inhibit BCR-ABL 
functions and cure the disease. However,  reports have shown that Src kinases 
remain active following imatinib inhibition of BCR-ABL kinase activity in leukemic 
cells (Hu et al, 2006). These results explain the importance of signaling events that 
come from the kinase-dead receptors and the role of SFKs. Other mechanisms of 
getting resistance to the tyrosine kinase inhibitors are acquiring secondary mutations 
in the kinase domain of the receptors. Secondary mutations were noticed in the 
kinase domain of Kit or EGFR in 50% of the patients with GIST or non-small cell lung 
cancer that have acquired resistance to imatinib or gefitinib/erlotinib respectively 
(Kobayashi et al, 2005;Tamborini et al, 2004). Secondary mutations in the kinase 
domain are called gatekeeper mutations. These gate keeper mutations prevent the 
binding of receptor to the kinase inhibitor (by preventing the hydrogen bond formation 
between inhibitor and receptor (Daub et al, 2004). Another mechanism that 
contributes the resistance to kinase inhibitors is a “kinase switch”. This mechanism 
involves activation of another kinase that is other than primarily targeted. Different Discussion 
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studies have shown activation of PDGFR (due to secondary mutations) in GIST 
patients, where primarily Kit was targeted (Debiec-Rychter et al, 2005). 
Therefore, RTKs may not be the ideal target kinases for tyrosine kinase inhibitors in a 
Cbl mutation–driven disease. Instead, SFKs may be interesting target kinases, for 
which inhibitors are readily available. Dasatinib, for example, is a multitargeted 
kinase inhibitor of BCR-ABL, SFKs, Kit, PDGFR,  and ephrin A receptor kinases 
(Lombardo et al, 2004;Nam et al, 2005;Schittenhelm et al, 2006) . It also emerged as 
a potent inhibitor of imatinib-resistant protein tyrosine kinase activation loop mutants 
of Kit, and it is able to induce apoptosis in mast cell and leukemic cell lines 
expressing these mutations (Shah et al, 2006) .  
The data presented here demonstrate that SFKs play a critical role in the mechanism 
of transformation of Cbl mutants. AML blasts expressing Cbl mutants (or 
dysregulated Cbl function by other mechanisms) might be resistant to tyrosine kinase 
inhibitors targeted for Flt3 or Kit. Although direct Cbl mutations may be rare in AML, 
similar mechanisms in the RTK degradation machinery may be operational in a large 
proportion of AMLs. Further studies are required to determine whether kinase 
inhibitors targeted at both RTKs and SFKs may overcome this primary resistance to 
RTK inhibitors. 
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6  Zusammenfassung 
Die akute myeloische Leukämie (AML) ist eine Erkrankung hämatopoetischer Zellen, 
die durch einen Differenzierungsblock und die unkontrollierte Bildung unreifer 
hämatopoetischer Zellen oder Blasten charakterisiert ist. Dabei kommt es zu einer 
starken Einschränkung der normalen Hämatopoese, was letztlich ohne Behandlung 
zum Tod des Patienten führt. Die Entstehung einer AML wird grundsätzlich als 
Entwicklung angesehen, die in mehreren Schritten vonstatten geht. Genetische 
Veränderungen, wie Mutationen, Translokationen, Amplifikationen und Deletionen 
sind an der Pathogenese der AML beteiligt. Diese genetischen Veränderungen 
können in zwei Gruppen eingeteilt werden: solche die zu einem Proliferations- oder 
Überlebensvorteil führen (Klasse I Mutationen) und andere, die einen 
Differenzierungsblock hervorrufen (Klasse II Mutationen). Eine einzelne Mutation 
dieser Art ist nicht in der Lage alleine einer AML auszulösen. Während Kit-
Mutationen relativ selten sind, wird bei der Mehrzahl der AML-Patienten eine 
Überexpression des Kit Rezeptors gefunden. Der Kit-Rezeptor wird durch seinen 
Liganden „Stem Cell Factor“ (SCF) aktiviert. Die Aktivierung von Kit führt zur 
Rekrutierung von Signalmolekülen.  Sog. „Gain-of-function“-Mutationen von Kit 
führen zu einer konstitutiven Aktivierung des Rezeptors. Cbl-Proteine degradieren 
bekanntermaßen aktivierte Rezeptortyrosinkinasen (RTKs) durch Ubiquitinierung. Die 
Untersuchung der Signaltransduktion von RTKs wie Kit oder Flt3 und deren 
Degradation, ist für die Entwicklung neuer therapeutischer Strategien zu von enormer 
Wichtigkeit. Gegenstand der vorliegenden Untersuchung ist der Einfluss von Cbl-
Mutanten (Cbl-R420Q und Cbl-70Z) auf die Kit–vermittelte Signaltransduktion. Cbl-
R420Z wurde bei einem AML-Patienten gefunden, während Cbl-70Z in Maus-
Myelom-Studien identifiziert wurde. Diese Cbl Mutanten haben die E3-Ligase 
Aktivität, die eine wichtige Rolle beim Transfer der Ubiquitin Moleküle zum Zielprotein 
spielt, verloren. Aus der vorliegenden Studie können folgende Schlussfolgerungen 
gezogen werden. 
 
Schlussfolgerung 1: Cbl Mutationen vermitteln Faktor-unabhängiges 
Wachstum in Kooperation mit Kit. 
Um die Funktion der Cbl Mutanten zu untersuchen, führten wir Proliferationsassays 
durch. Wir konnten zeigen, dass Cbl Mutanten (Cbl-R420, Cbl-R70Z) in Kooperation 
mit Wildtyp-Kit in der Lage sind, eine myeloische Zellinie (32D) zu transformieren. Zusammenfassung 
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Ebenso führen die Cbl-Mutanten  zusammen mit Kit zu einem verstärkten Überleben 
von 32D Zellen. Die Expression der Cbl Mutanten alleine führte in diesen Zellen zu 
einem leicht erhöhten Überlebensvorteil, ohne jedoch eine Faktor-unabhängige 
Proliferation zu vermitteln. Ferner wurde in dieser Zelllinie das SCF-Abhängige 
Wachstum durch die Cbl-Mutanten verstärkt. Außerdem vermittelten die Cbl 
Mutationen klonales Wachstum in Kooperation mit Kit. Die akute myeloische 
Leukämie entsteht nicht aufgrund einer einzelnen Mutation, sondern aufgrund 
mehrerer kooperiernder Ereignisse oder Mutationen. Unsere Ergebnisse zeigen, 
dass überexprimierte RTKs mit mutierten untergeordneten Signalmolekülen in der 
Transformation myeloischer Zellen kooperieren. 
 
Schlussfolgerung 2:  Cbl Mutanten verhindern die Ubiquitinierung und 
Endozytose des Kit Rezeptors. 
Es ist bekannt, dass Cbl-Proteine negative Regulatoren von RTKs einschließlich Kit 
und Flt3 sind. Funktionell inaktivierende Mutanten von Cbl (RING oder linker domain) 
setzen die E3-Ligase Aktivität von Cbl außer Kraft. In der vorliegenden Arbeit konnte 
gezeigt werden, dass Cbl Mutanten die Ubiquitinierung des aktivierten Kit-Rezeptors 
hemmen können. Die Ubiquitinierung von RTKs führt oft zur Internalisierung des 
Rezeptors. Es konnte gezeigt werden, dass Cbl-Mutanten die Endozytose Kit 
Rezeptors hemmt. Cbl-R420Q hemmte die Ubiquitinierung und Endozytose effektiver 
als Cbl-70Z. 
 
Schlussfolgerung 3: Cbl Mutanten führen zu einer generalisierten Mastozytose 
und einer myeloproliferativen Erkrankung im Knochenmark. 
Die Cbl-R420Q-Mutante wurde in einem AML-Patienten gefunden. Deshalb wurde 
untersucht, ob diese Cbl-Mutante eine hämtologische Erkrankung auslösen kann. Die 
retrovirale Überexpression der Cbl-Mutanten in murinem Knochenmark führte nach 
Transplantation zu einer generalisierten Mastozytose, einer myeloproliferativen 
Erkrankung sowie in seltenen Fällen einer myeloische Leukämie. Ferner kam es 
durch die Cbl-Mutanten zu einer Splenomegalie. Außerdem wurde in allen Organen 
der mit den Cbl Mutanten transplantieren Mäusen (Milz, Leber, Knochenmark, Lunge, 
Niere, Herz), eine Mastzellinfiltration unterschiedlichen Ausmaßes gefunden.  Fast 
alle Empfänger von mit Cbl-Mutanten transduzierten Knochenmarkzellen 
entwickelten eine tödliche hämatologische Erkrankung, mit einer mittleren Latenzzeit Zusammenfassung 
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von 341 Tagen in der Cbl-R420Q Gruppe und 395 Tagen in der Cbl-70Z Gruppe. Die 
lange Latenzzeit könnte durch   die Notwendigkeit des Erwerbs weiterer Mutationen 
für die Ausbildung des Phänotyps  bedingt  sein. Nach unserem Kenntnisstand ist 
dieses der erste Bericht, eines in-vivo Modells zur Untersuchung von Cbl Mutationen 
in der malignen Transformation. 
 
Schlussfolgerung 4: Cbl-70Z bindet konstitutiv an Kit. 
Für die Funktion der Cbl-Mutanten ist eventuell eine direkte Bindung an Kit 
notwendig. Unsere Ko-Immunopräzipitationsstudien zeigten, dass Cbl-70Z an Kit, 
selbst in Abwesenheit des Kit-Liganden (SCF) bindet. Cbl-R420Q zeigt ebenfalls eine 
schwache Bindung an Kit in Abwesenheit von SCF. Die Stimulation mit SCF führte zu 
einer verstärkten Bindung der Cbl-Mutanten an Kit. 
 
Schlussfolgerung 5: Cbl Mutanten führen zu einer konstitutiven Aktivierung der 
Akt- und Erk-Signalwege. 
Die Überexpression von Kit WT mit den Cbl-Mutanten führt zu einer Faktor-
unabhängigen Proliferation. Dies deutet darauf hin, dass die Expression von Cbl-
Mutanten zu einer Deregulation Wachstum-kontrollierender Signaltransduktionswege 
führt. Unsere Untersuchungen zeigten eine konstitutive Aktivierung des Akt- und Erk-
Signalwegs in Gegenwart der Cbl-Mutanten und Kit. Diese Signalwege wurden in 
32D-Zellen durch die Cbl-Mutatanten alleine in Abwesenheit von IL3 nicht aktiviert. 
 
Schlussfolgerung 6: Cbl Mutanten verlängern SCF-Abhängige Signale. 
Die Art und Stärke der Aktivierung von RTKs wird durch deren Dergadation genau 
kontrolliert. Veränderungen oder Beeinträchtigungen der RTK-Degradation wirken 
sich auf Qualität und Stärke des RTK-Signals aus. In Unseren Untersuchungen 
verstärkten die Cbl-Mutatuinen das SCF-abhängige Wachstum. Ferner wurde die 
SCF-abhängige Aktivierung von Kit, Akt und Erk durch die Cbl-Mutationen verlängert.  
 
Schlussfolgerung 7: Kit ist in der Gegenwart von Cbl-70Z autophosphoryliert. 
In unseren Untersuchen führte die Expression von Cbl-70Z, nicht jedoch die von Cbl-
R420Q zu einer SCF-unabhängigne Autophosphorylierung von Kit. Diese Ergebnisse 
deuten auf funktionelle Unterschiede zwischen den beiden Cbl-Mutanten hin. Zusammenfassung 
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Schlussfolgerung 8: Für die Cbl-70Z vermittelte Transformation ist keine 
Kinase-Aktivität von Kit erforderlich. 
In der vorliegenden Untersuchung wurde analysiert, ob für die durch Kit und die Cbl-
Mutanten synergistisch vermittelte Transformation myeloischer Zellen, Kinase-
Aktivität des Kit-Rezeptors notwendig ist. Cbl-70Z zusammen mit Kinase-defizientem 
Kit (Kit-KD) vermittelt in der myeloischen Zelllinie  32D Faktor-unabhängiges 
Wachstum, während Cbl-R420Q zusammen mit Kit-KD nur einen schwachen 
Wachstumsvorteil vermittelte. Cbl-70Z  vermittelte ferner im Zusammenhang mit Kit-
KD ein vermehrtes Faktor-unabhängiges Überleben der Zellen. In  diesen Versuchen 
zeigte eine SCF-Stimulation keine Wirkung auf die Kinase-defizienten Kit-
Rezeptoren.  
 
Schlussfolgerung 9: Die Kinase-Aktivität von Flt3 ist für die Cbl-70Z vermittelte 
Transformation nicht notwendig. 
Cbl-70Z führt zusammen mit Kinase-defizientem Flt3 (Flt3-KD) zu Faktor-
unabhängigem Wachstum in 32D Zellen. Cbl-R420Q vermittelte zusammen mit Flt3-
KD keinen Wachstumsvorteil. Cbl-70Z führte zusammen mit Flt3-KD zu einem 
verstärkten Faktor-unabhängigen Überleben der Zellen. Ähnlich wie beim Kit-
Rezeptor, zeigte Flt3-KD keine Phosphorylierung nach Ligandenstimulation. 
Zusammen mit den unter Schlussfolgerung 8 dargelegten Ergebnissen zeigen 
unsere Daten, dass für die Cbl-70Z vermittelte Transformation keine RTK Kinase-
Aktivität erforderlich ist. 
 
Schlussfolgerung 10: Die durch Cbl-70Z induzierte Transformation wird durch 
Akt vermittelt.  
Die Tatsache, dass die Cbl-70Z induzierte Transformation keine Kinase-Aktivität der 
kooperiertenden Rezeptortyrosinkinase erfordert, legt nahe, dass die Transformation 
in diesen Zellen durch andere Signalwege vermittelt wird. Unsere Ergebnisse deuten 
darauf hin, dass die Cbl-70Z induzierte Transformation nicht durch Erk- oder STAT-
abhängige Signalwerge vermittelt wird. Außerdem führte Cbl-70Z zu keiner 
Autophosphorylierung der Kinase-defizienten Rezeptoren. Jedoch zeigte sich, dass 
die Aktivierung von Akt für die Cbl-70Z-induzierte Transformation im Zusammenspiel 
mit Kit-KD bzw. Flt3-KD verantwortlich ist. Unsere Untersuchungen zeigten ferner, 
dass die Kinase-Aktivität von Kit für dessen Ubiquitinierung notwendig ist, da keine Zusammenfassung 
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Ubiuquitinierung des Kinase-defizienten  Rezeptors in Anwesenheit von SCF 
beobachtet wurde.  
 
Schlussfolgerung 11: Die Rolle von „Src-Family“-Kinasen (SFKs) in der Cbl-
70Z vermittelten Transformation. 
SFKs spielen bekanntermaßen eine wichtige Rolle bei der Vermittlung intrazellulärer 
Signale, insbesondere von Zytokinrezeptoren. Diese Rezeptoren haben keine 
Tyrosin-Kinase Aktivität. Da wir bei der durch die Cbl-Mutanten im Synergismus mit 
RTKs vermittelten Proliferation eine Tyrosin-Kinase-Unabhängikeit beobachteten, 
könnten SFKs in der Cbl-70Z vermittelten Transformation eine Rolle spielen. In 
unseren Untersuchungen führten die Cbl-Mutanten zu einer erhöhten Aktivität von 
SFKs. Die Hemmung von SFKs resultierten in einer Verminderung von durch Cbl-
Mutanten induzierter Proliferation bzw. klonalem Wachstum. Ferner konnten wir eine 
Bindung von Fyn an Cbl nachweisen.  Es konnte weiterhin eine Interaktion zwischen 
Cbl-70Z, SFKs und Kit-KD gezeigt werden. Außerdem ist die Kinase-Aktivität von 
SFKs für die Bindung an Cbl notwendig, da diese Bindung durch PP-2, eine SFK-
Inhibitor gehemmt werden kann. 
 
Schlussfolgerung 12: Kinase-Aktivität ist nicht notwendig. 
Im Zusammenhang mit Krebserkrakungen wird oft eine Deregulation von 
Rezeptortyrosinkinasen beobachtet und zwischenzeitlich ist eine große Anzahl von 
Tyrosinkiaseionhibitoren entwickelt worden. In der vorliegenden Studie wurden, zur 
Untersuchung der Notwendigkeit der Tyrosinkinase-Aktivität für die Cbl-70Z 
vermittelte Transformation, die Tyrosinkinase-inhibitoren Imatinib und Dasatinib 
verwendet. Imatinib  hemmt Bcr-abl, Kit und den PDGFR, während Dasarinib 
zusätlich zu den genannten RTKs SFKs hemmt. Imatinib hemmte die Proliferation 
von Zellen mit Kit WT und Cbl-70Z deutlich stärker als in Zellen mit Kinase-
defizientem Kit (Kit-KD) und Cbl-70Z, aber insgesamt in deutlich geringerem Ausmaß 
als Dasatinib. Dies deutet an, dass die Kit-Aktivität wichtig, aber nicht unabdingbar 
für die Cbl-70Z induzierte Transformation ist. Dasatinib und PP-2 (ein SFK-Inhibitor), 
hemmten die Phosphorylierung voin Cbl und Akt, was auf eine Rolle der SFKs 
„upstream“ von Cbl und Akt hinweist. SFKs sind deshalb ein wichtiger Bestandteil 
des Komplexes aus Kinase-defizienten RTKs und Cbl-Mutanten und ihre Hemmung 
verhindert die Transformation durch Cbl-Mutanten. Zusammenfassung 
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Unsere Untersuchungen zeigen, dass Rezeptortyrosinkinasen nicht in jedem Fall die 
besten Ansatzpunkte für therapeutische Interventionen bei transformierten 
myeloischen Zellen sind. Eine konstitutive Aktivierung von Src-Family-Kinases wurde 
in AML-Zellinien und in frisch isolierten primären Zellen von AML-Patienten 
beobachtet. Deshalb könnten SFKs attraktive Zielmoleküle zukünftiger Therapien 
sein, für die es bereits Inhibitoren, wie Dasatinib,  gibt. Zusammenfassend zeigt die 
vorliegende Studie eine wichtige Rolle von Cbl, Kit und SFKs bei der Transformation 
myeloischer Zellen. 
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+          Plus 
_          Minus 
%          Percent 
4H          Four-Helix-bundle 
A          Alanine 
AML          Acute Myeloid Leukemia 
ALL          Acute Lymphocytic Leukemia 
aUPD         acquired Uniparental Disomy  
BCR          B-Cell Receptor 
BM          Bone Marrow 
BSD          Blasticidine 
CBF          Core Binding Factor 
CBL          Casitas B-lineage Lymphoma 
CLL          Chronic Lymphocytic Leukemia 
CML          Chronic Myeloid Leukemia       
CSF1R        Colony Stimulating Factor 1Receptor 
C          Cysteine 
°C          Centigrade 
CO2          Carbon dioxide 
D          Aspartic acid 
DMEM        Dulbecco's modified eagle medium 
DMSO        Dimethyl Sulfoxide 
eGFP         Enhanced Green Fluorescent Protein 
EC          Extracellular 
ECL          Enhanced chemiluminiscence 
EGFR         Epidermal Growth Factor Receptor 
EDTA         Ethylene Diamine Tetra acetic Acid 
EGTA         Ethylene Glycol Tetra acetic Acid 
EPO          Erythropoietin 
Erk          Extracellular regulated kinase 
et. al.          Et alia  
FACS         Fluorescence Activated Cell Sorter  Abbreviations 
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FCS          Fetal Calf Serum 
FGFR         Fibroblast Growth Factor Receptor 
FL          Flt3 Ligand 
Flt3          FMS-like Tyrosine Kinase 3 
Flt3-ITD  FMS-like Tyrosine Kinase 3-  Internal Tandem 
Duplication   
FLt3-KD  FMS-like Tyrosine Kinase 3 Kinase-Dead 
G  Glycine 
GFP  Green Fluorescent Protein  
GIST  Gastrointestinal Stromal Tumors 
Gy  Gray 
Grb2  Growth factor receptor-bound protein 2  
3H  Tritium 
HA  Hemagglutinin   
HE  Hematoxylin and Eosin 
HECT  Homologous to the E6-AP Carboxyl Terminus 
HGF  Hepatocyte Growth Factor 
Hrs  Hours 
HSC  Hematopoietic Stem Cell 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSPC  Hematopoietic Stem and Progenitor Cell 
HZ4-FeSV  Hardy-Zuckerman 4 Feline Sarcoma Virus 
Ig  Immunoglobulin 
IL-3  Interleukin-3 
IMDM  Iscove's Modified Dulbecco's Medium   
IRES  Internal Ribosome Entry Site 
ITAM  Immunoreceptor tyrosine based activation motif 
JAK  Janus Kinases 
JMD  Juxtamembrane domain 
K  Lysine 
KD  Kilo Dalton 
Kg  Kilogram 
Kit-KD  Kit Kinase-Dead 
LZ  Leucine Zipper Abbreviations 
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MAPK  Mitogen-Activated Protein Kinase 
MBq  Megabecquerel 
mg  Milligram 
Min  Minutes 
ml   Milliliter 
μCi  Microcurie 
μg                   Microgram 
ml  Milliliter 
μF  Microfarad 
μl   Microliter 
μM   Micromolar 
mM  MilliMolar 
mm  Millimeter 
mg  Milligram 
MC  Mast Cells 
MDS  Myelodysplasia 
MPD  Myeloproliferative diseases 
MPP  Multipotent progenitor cells 
MPN  Myeloproliferative Neoplasams 
N  Asparagine 
NACE  Naphthol AS-D Chloroacetate Esterase  
NaCl  Sodium Chloride 
NaF  Sodium Fluoride 
ng  nano gram 
nM  nano Molar   
NP-40  nonyl phenoxylpolyethoxylethanol 
PBS  Phosphate Buffered Saline 
PE  Phycoerythrin 
PI-3-Kinase        Phosphoinositide-3-Kinase 
PDGFR  Platelet Derived Growth Factor Receptor  
p
H   potential Hydrogen 
PLAT-E  Platinum-E 
PKC  Protein Kinase C 
PTKs  Protein Tyrosine Kinases Abbreviations 
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Q  Glutamine 
R  Arginine 
RING  Really Interesting New Gene 
RNA  Ribonucleic Acid 
RPMI  Roswell Park Memorial Institute 
RTKs  Receptor Tyrosine Kinases  
RBC          Red Blood Cell 
SDS          Sodium Dodecyl Sulphate 
SDS-PAGE  Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis     
SFKs          Src Family Kinases 
SH2          Src Homology 2 
SH3          Src Homology 3 
SHP1         SH2 domain containing phophatase-1 
SL          Steel Locus 
SCF          Stem Cell Factor 
Ser          Serine 
STAT         Signal transducer and activator of transcription 
TCL          Total Cell Protein 
TCR          T-Cell Receptor 
Thr          Threonine 
TKB          Tyrosine Kinase Binding 
TKD          Tyrosine Kinase Domain 
TPO          Thrombopoietin 
Tyr          Tyrosine 
UBA          Ubiquitin Binding Associated 
V          Valine 
V          Volts 
VEGFR        Vascular Endothelial Growth Factor Receptor 
WEHI         Walter and Elisa Hall Institute 
Y          Tyrosine 
ZnCl2         Zinc Chloride 
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